US20110182816A1 - ANTIBODY AGAINST OXIDIZED LDL/ß2GPI COMPLEX AND USE OF THE SAME - Google Patents
ANTIBODY AGAINST OXIDIZED LDL/ß2GPI COMPLEX AND USE OF THE SAME Download PDFInfo
- Publication number
- US20110182816A1 US20110182816A1 US13/000,319 US200913000319A US2011182816A1 US 20110182816 A1 US20110182816 A1 US 20110182816A1 US 200913000319 A US200913000319 A US 200913000319A US 2011182816 A1 US2011182816 A1 US 2011182816A1
- Authority
- US
- United States
- Prior art keywords
- antibody
- seq
- amino acid
- arteriosclerosis
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000003384 imaging method Methods 0.000 claims abstract description 33
- 238000011503 in vivo imaging Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 108
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 93
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 79
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 65
- 108010071584 oxidized low density lipoprotein Proteins 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 32
- 239000012216 imaging agent Substances 0.000 claims description 28
- 241001465754 Metazoa Species 0.000 claims description 25
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 18
- 238000012216 screening Methods 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 57
- 239000013598 vector Substances 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 42
- 239000000427 antigen Substances 0.000 description 39
- 102000036639 antigens Human genes 0.000 description 39
- 108091007433 antigens Proteins 0.000 description 39
- 238000002591 computed tomography Methods 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 30
- 239000013604 expression vector Substances 0.000 description 22
- 108090000765 processed proteins & peptides Proteins 0.000 description 21
- 238000002823 phage display Methods 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 230000027455 binding Effects 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 239000012634 fragment Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 102000004196 processed proteins & peptides Human genes 0.000 description 14
- 230000009257 reactivity Effects 0.000 description 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000000799 fluorescence microscopy Methods 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 238000002372 labelling Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- -1 for example Proteins 0.000 description 9
- 210000004408 hybridoma Anatomy 0.000 description 9
- 238000012744 immunostaining Methods 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 241000283707 Capra Species 0.000 description 8
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 102000007330 LDL Lipoproteins Human genes 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000002073 fluorescence micrograph Methods 0.000 description 8
- 235000009200 high fat diet Nutrition 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002255 enzymatic effect Effects 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 239000012118 Alexa Fluor 750 Substances 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 210000002376 aorta thoracic Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000004020 luminiscence type Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 210000004102 animal cell Anatomy 0.000 description 5
- 210000001765 aortic valve Anatomy 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000002600 positron emission tomography Methods 0.000 description 5
- 238000002603 single-photon emission computed tomography Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101150037123 APOE gene Proteins 0.000 description 4
- 241000701822 Bovine papillomavirus Species 0.000 description 4
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 108091006047 fluorescent proteins Proteins 0.000 description 4
- 102000034287 fluorescent proteins Human genes 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 238000002595 magnetic resonance imaging Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102000000853 LDL receptors Human genes 0.000 description 3
- 108010001831 LDL receptors Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010067902 Peptide Library Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 230000007910 cell fusion Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010968 computed tomography angiography Methods 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 101150102415 Apob gene Proteins 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 101710094648 Coat protein Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 101150074155 DHFR gene Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 241000724791 Filamentous phage Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241001631646 Papillomaviridae Species 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 101710083689 Probable capsid protein Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 101150117115 V gene Proteins 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000010805 cDNA synthesis kit Methods 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 238000013170 computed tomography imaging Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001008 atrial appendage Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000001444 catalytic combustion detection Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000053563 human MYC Human genes 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 230000008722 morphological abnormality Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 101150040383 pel2 gene Proteins 0.000 description 1
- 101150050446 pelB gene Proteins 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Definitions
- the present invention relates to antibodies against an oxidized LDL/ ⁇ 2 GPI complex, and non-invasive diagnostic methods for arteriosclerosis using the antibodies such as methods for identifying atherosclerotic lesion sites and methods for monitoring the therapeutic effects.
- Diagnostic methods for assessing the condition of arteriosclerosis include, for example, the four methods described below.
- Ankle-brachial pressure index When blood pressure is measured at the arm and ankle levels in the supine position, the ankle blood pressure is normally slightly higher. However, the narrowing of a blood vessel reduces the downstream blood pressure, which results in a decrease in the ratio of ankle blood pressure to brachial blood pressure (ABI). A decrease in ABI not only indicates arteriosclerosis in the artery of the lower limb but also suggests systemic arteriosclerosis.
- Pulse wave velocity test A method for estimating the progression of arteriosclerosis by assessing arterial stiffness. In healthy individuals, blood vessels are elastic and thus vascular walls absorb vibration, resulting in a reduction in pulse wave velocity. As arteriosclerosis advances, the wave velocity increases. Thus, the progression of arteriosclerosis can be estimated using the velocity as an indicator.
- Carotid ultrasound examination A method for estimating the progression of systemic arteriosclerosis by observing carotid arteries which run very close to the surface of skin and have an interior condition that is easy to observe by ultrasound.
- MR angiography MRA
- CT angiography CTA
- Angiography was used as a major diagnostic imaging method for vascular diseases, but image information that is almost comparable to angiography but obtained in a less invasive manner has become available.
- the advantages of CTA include: (1) high spatial resolution; (2) simple examination; and (3) superiority in detecting calcified lesions.
- ankle-brachial pressure index and “pulse wave velocity test” can neither identify the site of atherosclerosis nor diagnose the progression at each site. Thus, these methods only provide indirect scores to assess arteriosclerosis.
- carotid ultrasound examination is superior in that it enables direct graphical observation of the inside of blood vessels.
- condition of vascular wall is assessed based on the contrasting density and shape in ultrasonic images, and thus clinicians and laboratory technicians who conduct the test are required to have skills.
- the test cannot identify the site of atherosclerosis or diagnose the progression at individual sites in blood vessels other than the carotid artery.
- methods for monitoring the progression of arteriosclerosis include ELISA systems for measuring the oxidized LDL/ ⁇ 2 GPI complex in blood (Japanese Patent Nos. 3370334 and 3898680; WO2003/022866, WO2004/023141).
- ELISA for measuring the oxidized LDL/ ⁇ 2 GPI complex can be used to estimate the size but not the site of atherosclerotic plaque.
- An objective of the present invention is to provide antibodies against an oxidized LDL/ ⁇ 2 GPI complex, and non-invasive diagnostic methods for arteriosclerosis using the antibodies such as methods for identifying arteriosclerosis lesion sites and methods for monitoring the therapeutic effects.
- the present inventors selected antibodies applicable to in vivo imaging, specifically to visualize atherosclerotic plaques, in particular, the location and size of atheroma in the body. Then, the prevent inventors analyzed the specificities of the antibodies. The result showed that fluorescently labeled anti-oxidized LDL/ ⁇ 2 GPI complex antibodies that are specific to a particular epitope were effective for imaging.
- the present invention provides:
- an antibody comprising a heavy chain that comprises a heavy-chain variable region having the amino acid sequence of SEQ ID NO: 1;
- an antibody comprising a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO: 7, CDR2 having the amino acid sequence of SEQ ID NO: 8, and CDR3 having the amino acid sequence of SEQ ID NO: 9;
- an antibody comprising a light chain that comprises a light-chain variable region having the amino acid sequence of SEQ ID NO: 6;
- an imaging agent for visualizing an arteriosclerosis site which comprises the antibody of any one of [1] to [3]; [11] use of the antibody of any one of [1] to [3] for the manufacture of an imaging agent for visualizing an arteriosclerosis site; and [12] the antibody of any one of [1] to [3] for use in an imaging method for visualizing an arteriosclerosis site.
- FIG. 1 is diagrams showing antibody reactivities to immobilized antigen.
- the antibodies were monoclonal antibodies obtained by immunizing BALB/c mice with the oxidized LDL/ ⁇ 2 GPI complex as an antigen.
- the horizontal axis indicates antibody concentration, and the vertical axis indicates the absorbance.
- FIG. 2 is a diagram for assaying competitive nature of antigen in solution (competitive inhibition assay).
- FIG. 3 is graphs showing a test of competitive inhibition by antigen.
- the horizontal axis indicates antigen concentration in a liquid, and the vertical axis indicates the percent inhibition (%) determined when taking the absorbance in the absence of inhibitory antigen as 100%.
- 3H3 and 4C12 are antibodies that recognize ⁇ 2 GPI bound to oxidized LDL. These antibodies do not recognize free ⁇ 2 GPI.
- 2H6, 3D4, and 2A12 are antibodies reactive to free ⁇ 2 GPI.
- FIG. 4 is photographs showing fluorescent immunostaining of the aortic valve in arteriosclerosis-prone model mice (apoE ⁇ / ⁇ fed a high fat diet).
- A DAPI, nuclear stain
- B Mac3, macrophage-specific antibody
- C antibody 3H3
- D control.
- Mac3 stained atheroma formed via accumulation of foamy macrophages.
- 3H3 stained the same areas.
- FIG. 5 is photographs showing fluorescent immunostaining of the aortic valve in arteriosclerosis-prone model mice (apoE ⁇ / ⁇ fed a high fat diet). The photographs show results of fluorescent immunostaining using other antibodies against the oxidized LDL/ ⁇ 2 GPI complex. Antibodies positive for atheroma in the staining were only antibodies 3H3 and A.
- FIG. 6 is photographs showing IVIS 200 fluorescence imaging using specific antibody (reflection fluorescence microscopy).
- ApoE ⁇ / ⁇ mice were fed a high fat diet for six months or more. Imaging agents were administered to the mice at the caudal vein. After two to 24 hours, in vivo fluorescence was observed and photographed under inhalation anesthesia using IVIS 200. The ApoE ⁇ / ⁇ mice were observed after shaving, because their black hair absorbs fluorescence.
- Mice euthanized were thoracotomized. The heart and aorta were exposed, and a small incision was made in the right auricular appendage. Then, a needle was inserted into the left ventricle and the heart was perfused with 10 ml of cold PBS. The heart and aorta were excised and their reflection fluorescence microscopic images were recorded using IVIS 200.
- FIG. 7 is photographs showing IVIS 200 fluorescence imaging (excitation, 640 nm; emission, 720 nm).
- Experiment 1 physiological saline (PBS; control), Cy5.5-labeled antibody A, or Cy5.5-labeled antibody 3H3 was administered at the caudal vein to apoE ⁇ / ⁇ mice fed a high fat diet. Twenty four hours after administration, the mice were photographed alive for the full-body image after removing their thoracic skin. Then, the heart intact with thoracic aorta was excised and photographed.
- Experiment 2 Hearts and aortae excised from mice administered with PBS, Cy5.5-labeled antibody 2A12, or y5.5-labeled antibody 3H3. Administered 3H3 intensely stained the aortic root. Antibody A also stained to some extent; however, the fluorescence intensity is weaker as compared to 3H3. There was no stain in the case of 2A12.
- FIG. 8 is photographs showing three-dimensional imaging of arteriosclerosis using the specific antibody.
- A IVIS 200 fluorescence imaging using the specific antibody (reflection fluorescence microscopy);
- B IVIS 200 3D image obtained using transmitted light (left panel), CT 3D image before superimposing (middle panel), and the superimposed 3D image (right panel);
- C superimposed 3D images generated from IVIS fluorescence signal and 3D CT.
- FIG. 9 is photographs showing IVIS 200 fluorescence three-dimensional images before superimposing (upper panels, A) and superimposed images generated from IVIS 200 fluorescence signal and 3D CT (bottom panels, B).
- FIG. 10 is a diagram showing fluorescence intensity of Cy5.5 around the aortic root observed using IVIS 200.
- the fluorescence intensity was determined per unit area of the aortic root.
- the fluorescence of PBS-administered control mouse was taken as 1.0. When 3H3 was administered, fluorescence was three times stronger than the control. When other antibodies were administered, there was no significant change in the fluorescence intensity.
- FIG. 11 is a diagram showing the amino acid sequence of antibody 3H3. Each CDR is underlined.
- the present invention provides antibodies that bind to a complex of oxidatively modified LDL (oxidized LDL) and ⁇ 2 -glycoprotein I (oxidized LDL/ ⁇ 2 GPI complex).
- the complex is formed between oxidized LDL and ⁇ 2 GP in atherosclerotic plaques.
- ⁇ 2 GP is a serum glycoprotein.
- the antibodies of the present invention bind to the complex.
- antibodies of the present invention include those described below, but are not limited thereto:
- an antibody comprising a heavy chain that comprises a heavy-chain variable region having the amino acid sequence of SEQ ID NO: 1;
- an antibody comprising a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO: 7, CDR2 having the amino acid sequence of SEQ ID NO: 8, and CDR3 having the amino acid sequence of SEQ ID NO: 9;
- an antibody comprising a light chain that comprises a light-chain variable region having the amino acid sequence of SEQ ID NO: 6;
- the present invention also provides antibodies that bind to the same epitope as an antibody of the present invention that binds to the complex of oxidized LDL and ⁇ 2 -glycoprotein I (oxidized LDL/ ⁇ 2 GPI complex).
- Such antibodies recognize a particular epitope on the oxidized LDL/ ⁇ 2 GPI molecule which is a complex formed with oxidized LDL.
- Whether an antibody recognizes the same epitope as another antibody can be confirmed, for example, by their competition for the epitope, although the test method is not limited thereto.
- the competition between antibodies can be assessed by competitive binding assays.
- the method includes ELISA, fluorescence resonance energy transfer (FRET), and fluorometric microvolume assay technology (FMATTM).
- the amount of a particular antibody bound to antigen is indirectly correlated with the binding activity of a competitor antibody candidate (test antibody), which competes for the binding to the same epitope. Specifically, as the amount or affinity of a test antibody for the same epitope increases, the amount of an antibody bound to the antigen decreases, and the amount of test antibody bound to the antigen increases.
- an appropriately labeled antibody is added to the antigen together with a test antibody, and then the bound antibody is detected using the label.
- the amount of an antibody bound to the antigen can be readily determined by labeling the antibody in advance.
- labels are not particularly limited; however, appropriate labeling methods are selected depending on the technique.
- labeling methods include, for example, fluorescent labeling, radiolabeling, and enzyme labeling.
- antibody that recognizes the same epitope refers to an antibody that can reduce the amount of labeled antibody bound by at least 50%, when a test antibody is used at a concentration typically 100 times higher, preferably 80 times higher, more preferably 50 times higher, even preferably 30 times higher, and still preferably 10 times higher than the IC 50 of the non-labeled antibody, where IC 50 is defined as a concentration of a non-labeled antibody at which the amount of the labeled antibody bound is decreased by 50% due to the binding of the non-labeled antibody.
- the antibodies of the present invention include both polyclonal and monoclonal antibodies. Methods for preparing and purifying monoclonal and polyclonal antibodies are known in the field, and described, for example, in “Harlow and Lane, Antibodies: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1988)”.
- the antibodies of the present invention also include recombinant antibodies such as humanized antibodies and chimeric antibodies.
- “Humanized antibody” refers to an antibody whose structure is similar to that of a human antibody.
- Such humanized antibodies and chimeric antibodies include human-type chimeric antibodies (for example, antibodies in which some portions have been humanized, antibodies whose CH2 region has been humanized, antibodies whose Fc domain has been humanized, antibodies whose constant region has been humanized), CDR-grafted humanized antibodies whose constant and variable regions have been humanized except their complementarity determining regions (CDRs) (P. T. Johons et al., Nature 321, 522 (1986)), and completely humanized antibodies.
- CDRs complementarity determining regions
- Improvement methods for enhancing the antigen binding activity of a CDR-grafted human-type antibody include: methods for selecting human antibody FRs that are highly homologous to the mouse antibody, methods for producing highly homologous humanized antibodies, and methods for substituting amino acids in FR after grafting mouse CDRs to human antibodies (see U.S. Pat. Nos. 5,585,089, 5,693,761, 5,693,762, and 6180370; EP Nos. 451216 and 682040; Japanese Patent No. 2828340). Such methods can be used to prepare CDR-grafted human-type antibodies of the present invention.
- Human-type chimeric antibodies can be produced, for example, by substituting a human anybody constant region for the constant region of an above-described antibody having the structure of an H-chain variable region and/or the structure of an L-chain variable region described above.
- Such human antibody constant regions include known human antibody constant regions.
- a method for producing human-type chimeric antibodies is described below as an example.
- mRNA is extracted from hybridomas producing a mouse antibody against a particular target antigen.
- cDNA is synthesized from the mRNA by a conventional method.
- the synthesized cDNA is inserted into a vector to construct a cDNA library.
- a vector carrying H-chain and L-chain genes is selected from the cDNA library using H-chain gene and L-chain gene fragments as a probe.
- the sequences of the H-chain variable region and L-chain variable region genes are determined by sequencing the insert in the selected vector.
- DNA encoding the H-chain variable region is constructed based on the sequence data obtained as described above by chemical synthesis, biochemical cleavage/ligation, or the like.
- the resulting DNA that encodes the H-chain variable region is ligated with a DNA encoding human H-chain constant region, and then inserted into an expression vector to construct an expression vector for H chain.
- expression vectors include, for example, SV40 virus-based vectors, EB virus-based vectors, and papilloma virus (BPV)-based vectors, but are not limited thereto.
- expression vectors for L chain are constructed by the same method.
- Host cells are co-transformed with the H-chain expression vectors and L-chain expression vectors.
- Preferred host cells include CHO cells (Chinese hamster ovary) (A. Wright & S. L. Morrison, J. Immunol.
- Transformation can be preferably carried out by using electroporation, a lipofectin method (R. W. Malone et al., Proc. Natl. Acad. Sci. USA 86, 6077 (1989); P. L. Feigner et al., Proc. Natl. Acad. Sci. USA 84, 7413 (1987)), calcium phosphate method (F. L. Graham & A. J. van der Eb, Virology 52, 456-467 (1973)), DEAE-Dextran method, and the like.
- the transformants are cultured, and then human-type chimeric antibodies are isolated from the transformants or culture media.
- Antibodies can be isolated or purified by an appropriate combination of methods such as centrifugation, ammonium sulfate fractionation, salting out, ultrafiltration, affinity chromatography, ion exchange chromatography, and gel filtration chromatography.
- human-type CDR-grafted antibodies can be produced, for example, by the following method.
- FRs framework regions which sandwich CDRs are selected.
- Three methods are available for selecting FRs.
- the first method uses human antibody frames with known three dimensional structures, such as NEWM and REI (Riechmann L. et al., Nature 332, 323-3Z7 (1988); Tempst, P R. et al., Protein Engineering 7, 1501-1507 (1994); Ellis J H. et al., J. Immunol 155, 925-937 (1995)).
- the second method uses FRs of a human antibody variable region that is most homologous to a mouse antibody variable region of interest, in which the human antibody variable region is selected from databases (Queen C.
- FR amino acid sequences to be used also include amino acid sequences resulting from modification of the amino acid sequence of a selected human FR, as long as the human-type CDR-grafted antibody produced from it has the activity of specifically binding to the target antigen.
- the resulting antibody is very likely to retain the antibody properties.
- the number of amino acids to be modified is preferably 30% or less in a whole FR, more preferably 20% or less in a whole FR, and still more preferably 10% or less in a whole FR.
- DNAs encoding H-chain and L-chain variable regions are designed by combining the above-described CDRs with FRs selected by any one of the methods described above. Based on this design, DNAs encoding H-chain variable regions and DNAs encoding L-chain variable regions are prepared by chemical synthesis, biochemical cleavage/ligation, or the like. Then, an H-chain expression vector is constructed by inserting into an expression vector the H-chain variable region-encoding DNA, along with a DNA encoding an H-chain constant region of human immunoglobulin. Likewise, an L-chain expression vector is constructed by inserting into an expression vector the L-chain variable region-encoding DNA, along with a DNA encoding an L-chain constant region of human immunoglobulin. Expression vectors include, for example, SV40 virus-based vectors, EB virus-based vectors, and papilloma virus (BPV)-based vectors, but are not limited thereto.
- H-chain expression vector is constructed by inserting into an expression vector the
- Host cells are co-transformed with the H-chain expression vectors and L-chain expression vectors prepared by the method described above.
- Such preferred host cells include CHO cells (Chinese hamster ovary) (A. Wright & S. L. Morrison, J. Immunol. 160, 3393-3402 (1998)) and SP2/0 cells (mouse myeloma) (K. Motmans et al., Eur. J. Cancer Prev. 5, 512-519 (1996); R. P. Junghans et al., Cancer Res. 50, 1495-1502 (1990)). Transformation can be preferably carried out by using electroporation, a lipofectin method (R. W. Malone et al., Proc. Natl.
- the transformants are cultured, and then human-type CDR-grafted antibodies are isolated from the transformants or culture media.
- Antibodies can be isolated or purified by an appropriate combination of methods such as centrifugation, ammonium sulfate fractionation, salting out, ultrafiltration, affinity chromatography, ion exchange chromatography, and gel filtration chromatography.
- desired human antibodies with antigen-binding activity can be obtained by sensitizing human lymphocytes in vitro with an antigen of interest or cells expressing an antigen of interest; and fusing the sensitized lymphocytes with human myeloma cells such as U266 (see Japanese Patent Application Kokoku Publication No. (JP-B) H01-59878 (examined, approved Japanese patent application published for opposition)).
- JP-B Japanese Patent Application Kokoku Publication No.
- desired human antibodies can also be obtained by using an antigen of interest to immunize transgenic animals that have the entire repertoire of human antibody genes (see International Patent Application WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).
- antibodies and antibody fragments can be isolated from an antibody phage library produced by using the technique described by McCafferty et al. (Nature, 348: 552-554 (1990)). Clackson et al. (Nature, 352: 624-628 (1991)) and Marks et al. (J. Mol. Biol., 222: 581-597 (1991)) reported isolation of mouse and human antibodies using phage libraries.
- the bacteriophage (phage) display is one of the well-known techniques that enable one to search a large oligopeptide library and identify library members having the ability to specifically bind to a target polypeptide.
- the phage display is a technique that displays various polypeptides as a fusion protein with the coat protein on the surface of bacteriophage particles (Scott, J. K. and Smith G. P. Science 249: 386 (1990)).
- An advantage of phage display is that it enables rapid and effective categorization of a large library of selectively randomized protein mutants (or random cDNA clones) for the sequences that bind with high affinity to a target molecule.
- the phage display of peptide library (Cwirla, S.
- Categorization in a phage library of random mutants requires a method for constructing and propagating a vast number of mutants; an affinity purification method using a target receptor; and a method for assessing the enhanced binding (see U.S. Pat. Nos. 5,223,409, 5,403,484, 5,571,689, and 5663143).
- phage display methods use filamentous phages; however, known phage display methods also include ⁇ phage display system (WO 95/34683; U.S. Pat. No. 5,627,024), T4 phage display system (Ren J. et al., Gene 215: 439 (1998); Zhu et al., Cancer Research, 58 (15):3209-3214 (1998); Jiang et al., Infection & Immunity, 65(11): 4770-4777 (1997); Ren et al., Gene, 195(2): 303-311 (1997); Ren, Protein Sci.
- WO 97/35196 describes a method for isolating affinity ligands, in which bound ligands are selectively isolated by contacting a phage display library with a first solution that allows binding of the ligand to a target molecule and then with a second solution where affinity ligand does not bind to the target molecule.
- WO 97/46251 describes a method for isolating high affinity-binding phages in which a random phage display library is treated by biopanning using an affinity-purified antibody, followed by isolation of bound phages, and then by micropanning in the wells of microplates.
- WO 97/47314 describes the use of substrate subtraction library in identifying enzymatic specificity using a combinatorial library which may be a phage display library.
- WO 97/09446 describes a method for selecting enzymes that are suitable as a washing reagent to be used in phage display. Other methods for selecting proteins that bind in a specific manner are described in U.S. Pat. Nos. 5,498,538 and 5,432,018, and WO 98/15833. Methods for constructing and screening peptide libraries are described in U.S. Pat. Nos. 5,723,286, 5,432,018, 5,580,717, 5,427,908, 5,498,530, 5,770,434, 5,734,018, 5,698,426, 5,763,192, and 5,723,323.
- variable regions of human antibodies can be expressed as single chain antibodies (scFvs) on the surface of phages to select phages that bind to an antigen.
- the DNA sequences encoding the variable regions of human antibodies that bind to the antigen can be determined by analyzing the genes of selected phages.
- human antibodies can be prepared by constructing appropriate expression vectors carrying these sequences and expressing the antibodies in adequate hosts introduced with the expression vectors. Such methods are already known (see WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, and WO 95/15388).
- the phage display technique (McCafferty et al., Nature 348: 552-553 (1990)) can be used to produce human antibodies and antibody fragments in vitro from the immunoglobulin variable (V) domain gene repertoire of a non-immunized donor.
- V domain gene is cloned in frame with a coat protein gene of filamentous bacteriophage, for example, M13 or fd, and then displayed as a functional antibody fragment on the surface of phage particles. Since filamentous particles contain a single-stranded DNA copy of the phage genome, screening based on the functional properties of antibody results in selection of genes encoding an antibody having the properties.
- phages mimic some characteristics of B cells.
- Phage display can be carried out in various modes; see, for example, Johnson, Kevin S, and Chiswell, David J., Current Opinion in Structural Biology 3: 564-571 (1993).
- V gene segments available for phage display.
- Clackson et al. (Nature, 352: 624-628 (1991)) have isolated numerous various anti-oxazolone antibodies from a small random combinatorial library of V genes derived from spleens of immunized mice.
- V gene repertoire of a non-immunized human donor can be constructed, and antibodies against numerous various antigens (including self antigens) can be isolated by using the technique described in either of the following documents without modification: Marks et al., J. Mol. Biol. 222: 581-597 (1991) or Griffith et al., EMBO J. 12: 725-734 (1993). See also U.S. Pat. Nos. 5,565,332 and 5,573,905.
- the antibodies of the present invention also include functional antibody fragments such as Fab, Fab′, F(ab′) 2 , Fv, scFv, dsFv, Diabodies, and sc(Fv)2. Multimers (for example, dimers, trimers, tetramers, and polymers) of such a functional antibody fragment are also included in the antibodies of the present invention.
- Fab is a fragment with a molecular weight of about 50,000 that consists of L-chain and H-chain variable regions, and an H chain fragment containing C H 1 domain and a portion of hinge region.
- Fab is obtained by digesting IgG with papain in the presence of cysteine.
- an antibody described above can be digested with papain to prepare such Fab.
- a DNA encoding a portion of H chain and the L chain of an antibody described above is inserted into an appropriate vector.
- Fab can be prepared from transformants obtained by transformation using the vector.
- Fab′ is a fragment with a molecular weight of about 50,000 obtained by cleaving the disulfide bond between the H chains of F(ab′) 2 described below.
- F(ab′) 2 can be obtained by treating an above-described antibody by pepsin digestion, followed by cleavage of disulfide bond with a reducing agent.
- Fab′ can be prepared by genetic engineering using DNA encoding Fab′.
- F(ab′) 2 is a fragment with a molecular weight of about 100,000 obtained by digesting IgG with pepsin.
- F(ab′) 2 is constituted by two (Fab′) fragments linked together via disulfide bond, each of which consists of L-chain and H-chain variable regions, and an H chain fragment containing C H 1 domain and a portion of hinge region.
- F(ab′) 2 can be prepared by digesting an above-described antibody with pepsin.
- F(ab′) 2 can be prepared by genetic engineering using F(ab′) 2 -encoding DNAs.
- Fv can be prepared by digesting an antibody into antibody fragments with an enzyme, for example, papain or pepsin.
- genes encoding antibody fragments are constructed and inserted into an expression vector.
- Fv can be expressed in appropriate host cells using the vector (see, for example, Co, M. S. et al., J. Immunol. 152, 2968-2976 (1994); Better, M. and Horwitz, A. H. Methods in Enzymology 178, 476-496 (1989); Plueckthun, A. and Skerra, A. Methods in Enzymology 178, 476-496 (1989); Lamoyi, E., Methods in Enzymology 121, 652-663 (1989); Rousseaux, J. et al., Methods in Enzymology 121, 663-669 (1989); Bird, R. E. et al., TIBTECH 9, 132-137 (1991)).
- scFv is a single-chain antibody fragment in which the C terminus of one Fv chain consisting of H-chain and L-chain variable regions is linked via an appropriate peptide linker to the N terminus of the other Fv chain.
- peptide linkers include, for example, flexible (GGGGS) 3 .
- GGGGS flexible
- a DNA encoding an scFv antibody is constructed using DNAs encoding the H-chain variable region and L-chain variable region of an above-described antibody and a DNA encoding a peptide linker, and then inserted into an appropriate vector. Transformants are obtained by transformation with the resulting vector. scFv can be prepared from the transformants.
- dsFv is an Fv fragment whose H-chain and L-chain variable regions are stabilized with a disulfide bond formed by introducing Cys residues at appropriate positions in the H-chain and L-chain variable regions.
- the position at which Cys residue is to be introduced is determined based on the conformation predicted by molecular modeling. In the present invention, for example, the conformation is predicted from the amino acid sequences of H-chain and L-chain variable regions of an above-described antibody.
- DNAs are constructed to encode H-chain and L-chain variable regions that have been introduced with mutations based on the prediction, and inserted into an appropriate vector. Transformants are obtained by transformation with the resulting vector. dsFv can be prepared from the transformants.
- multimers of antibody fragments can be prepared by linking scFv antibodies, dsFv antibodies, and the like via appropriate linkers, or fusing them to streptavidin.
- Fusion antibodies or labeled antibodies can be prepared from the antibodies (including antibody fragments) of the present invention by fusing or linking the antibodies with low molecular weight compounds, proteins, labeling substance, or the like.
- labeling substances include radioactive substances such as 125 I.
- Diabody refers to a bivalent antibody fragment constructed by gene fusion (Holliger P et al., Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993); EP 404,097; WO 93/11161).
- Diabodies are dimers consisting of two polypeptide chains, where each polypeptide chain has a VL and a VH linked via a linker short enough to prevent interaction of these two domains, for example, a linker of about five residues. The VL and VH linked together in a single polypeptide chain will form a dimer because the linker between them is too short to form a single-chain variable region fragment.
- Diabodies can be prepared by treating an antibody with an enzyme, for example, papain or pepsin, to generate antibody fragments, or by constructing DNAs encoding those antibody fragments and introducing them into expression vectors, followed by expression in an appropriate host cell (see, for example, Co, M. S. et al., J. Immunol. 152, 2968-2976 (1994); Better, M. and Horwitz, A. H., Methods Enzymol. 178, 476-496 (1989); Pluckthun, A. and Skerra, A., Methods Enzymol.
- an enzyme for example, papain or pepsin
- sc(Fv)2 is a single-chain minibody produced by linking two VHs and two VLs using linkers and such (Hudson et al., J. Immunol. Methods 231: 177-189 (1999)).
- sc(Fv) 2 can be produced, for example, by linking scFvs via a linker.
- the antibodies of the present invention also include fusion proteins in which an above-described antibody is fused with other peptides or proteins.
- the fusion protein can be prepared by linking a polynucleotide encoding an antibody of the present invention with a polynucleotide encoding a different peptide or polypeptide in frame, and introducing this into an expression vector and expressing it in a host. It is possible to use techniques known to those skilled in the art.
- Such a peptide or polypeptide to be fused with an antibody of the present invention include known peptides, for example, such as FLAG (Hopp, T. P.
- 6 ⁇ His consisting of six His (histidine) residues, 10 ⁇ His, influenza hemagglutinin (HA), human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40 T antigen fragment, lck tag, ⁇ -tubulin fragment, B-tag, and Protein C fragment.
- polypeptides to be fused with an antibody of the present invention include, for example, GST (glutathione-S-transferase), HA (influenza hemagglutinin), ⁇ -galactosidase, and MBP (maltose-binding protein).
- the antibodies of the present invention also include antibodies linked to a labeling substance.
- Such labeling substances include, but are not limited to, enzymatic luminescence (luciferase), luminescent low-molecular-weight substances, fluorescent proteins, fluorescent low-molecular-weight substances, and radionuclides.
- radionuclides include, but are not limited to, ⁇ -ray emitting nuclides such as 51 Cr, 59 Fe, 57 Co, 67 Ga, 75 Se, 81m Kr, 99m Tc, 111 In, 125 I, 131 I, 133 Xe, and 201 Tl, and positron-emitting nuclides such as 11 C, 13 N, 15 O, 18 F, 35m Cl, 76 Br, 45 Ti, 48 V, 60 Cu, 61 Cu, 62 Cu, 66 Ga, 89 Zr, 94m Tc, and 124 I. “m” represents nuclear isomer, which is apparent to those skilled in the art.
- Fluorescent labels and luminescent labels include those using enzymatic luminescence (luciferase) and those using fluorescence (fluorescent proteins such as GFP, DsRed, and Kusabira Orange; and fluorescent low-molecular-weight substances such as FITC, Cy5.5, and Alexa Fluor 750).
- labels that have reduced influence from the animal's intrinsic fluorescence, and labels that emit a signal with high skin permeability are more preferred.
- the present invention also provides DNAs encoding an antibody of the present invention, vectors inserted with the DNAs, and transformed cells introduced with the vectors.
- the vectors include, for example, M13 vectors, pUC vectors, pBR322, pBluescript, and pCR-Script.
- the vectors include pGEM-T, pDIRECT, and pT7, in addition to those described.
- DNAs encoding an antibody of the present invention, vectors inserted with the DNAs, and transformed cells introduced with the vectors are prepared by known methods.
- DNAs encoding an antibody of the present invention that binds to the oxidized LDL/ ⁇ 2 GPI complex include the following DNAs:
- an expression vector When an expression vector is used for expression in E. coli , for example, it should have the above-described characteristics which allow its amplification in E. coli . Additionally, when the host is E. coli such as JM109, DH5 ⁇ , HB101, or XL1-Blue, the vector must have a promoter that allows efficient expression in E. coli , for example, lacZ promoter (Ward et al. Nature 341: 544-546 (1989); FASEB J. 6: 2422-2427 (1992)), araB promoter (Better et al. Science 240:1041-1043 (1988)), or T7 promoter.
- lacZ promoter Ward et al. Nature 341: 544-546 (1989); FASEB J. 6: 2422-2427 (1992)
- araB promoter Secondetter et al. Science 240:1041-1043 (1988)
- T7 promoter T7 promoter
- the vector also includes pGEX-5X-1 (Pharmacia), “QIAexpress system” (QIAGEN), pEGFP, and pET (for this vector, BL21, a strain expressing T7 RNA polymerase, is preferably used as the host), in addition to the above-described vectors.
- the vector may comprise a signal sequence for polypeptide secretion.
- the pelB signal sequence Lei, S. P. et al. J. Bacteriol. 169: 4379 (1987)
- the vector can be introduced into host cell, for example, by the calcium chloride method or electroporation.
- the vector includes, for example, expression vectors derived from mammals (for example, pcDNA3 (Invitrogen), pEGF-BOS (Nucleic Acids Res. 18(17): 5322 (1990)), pEF, and pCDM8), insect cells (for example, “Bac-to-BAC baculovirus expression system” (GIBCO-BRL), pBacPAK8), plants (for example, pMH1 and pMH2), animal viruses (for example, pHSV, pMV, and pAdexLcw), retroviruses (for example, pZIPneo), yeasts (for example, “ Pichia Expression Kit” (Invitrogen), pNV11, and SP-Q01), and Bacillus subtilis (for example, pPL608 and pKTHSO).
- mammals for example, pcDNA3 (Invitrogen), pEGF-BOS (Nucleic Acids Res. 18(17): 5322 (1990)),
- the vector In order to express proteins in animal cells, such as CHO, COS, and NIH3T3 cells, the vector must have a promoter necessary for expression in such cells, for example, SV40 promoter (Mulligan et al. Nature 277:108 (1979)), MMTV-LTR promoter, EF1 ⁇ promoter (Mizushima et al. Nucleic Acids Res. 18: 5322 (1990)), CMV promoter, etc). It is even more preferable that the vector carries a gene for selecting transformants (for example, a drug-resistance gene that enables discrimination by a drug (such as neomycin and G418)). Vectors having such characteristics include, for example, pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.
- SV40 promoter Mulligan et al. Nature 277:108 (1979)
- MMTV-LTR promoter
- the following method can be used for stable gene expression and gene amplification in cells: CHO cells deficient in a nucleic acid synthesis pathway are introduced with a vector (for example, pCHOI) that carries a DHFR gene which compensates for the deficiency, and the gene is amplified using methotrexate (MTX).
- a vector for example, pCHOI
- MTX methotrexate
- the following method can be used for transient gene expression: COS cells whose chromosome contains a gene for expression of SV40 T antigen are transformed with a vector (such pcD) having an SV40 origin of replication. It is also possible to use replication origins derived from polyoma virus, adenovirus, bovine papilloma virus (BPV), or such.
- the expression vectors may further contain selection markers such as aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E. coli xanthine-guanine phosphoribosyltransferase (Ecogpt) gene, and dihydrofolate reductase (dhfr) gene.
- APH aminoglycoside transferase
- TK thymidine kinase
- Ecogpt E. coli xanthine-guanine phosphoribosyltransferase
- dhfr dihydrofolate reductase
- Host cells to be introduced with the vectors are not particularly limited, and include, for example, E. coli and various types of animal cells.
- the host cells can be used, for example, as production systems for expressing and producing the antibodies of the present invention.
- the polypeptide production systems include in vitro and in vivo production systems.
- the in vitro production systems include production systems using eukaryotic or prokaryotic cells.
- animal cells for example, animal cells, plant cells, and fungal cells can be used as the host.
- animal cells include mammalian cells (for example, CHO (J. Exp. Med. 108, 945 (1995)), COS, 3T3, myeloma, baby hamster kidney (BHK), HeLa, and Vero), amphibian cells (for example, Xenopus oocyte (Valle, et al., Nature 291, 338-340 (1981))), and insect cells (for example, Sf9, Sf21, and Tn5).
- mammalian cells for example, CHO (J. Exp. Med. 108, 945 (1995)
- COS for example, COS, 3T3, myeloma, baby hamster kidney (BHK), HeLa, and Vero
- amphibian cells for example, Xenopus oocyte (Valle, et al., Nature 291, 338-340 (1981)
- insect cells for example, Sf9, S
- CHO cells are particularly preferred for large-scale expression in animal cells.
- the vectors can be introduced into host cells, for example, by calcium phosphate methods, DEAE-dextran methods, methods using cationic liposome DOTAP (Boehringer-Mannheim), electroporation, and lipofection.
- the plant cells include, for example, Nicotiana tabacum -derived cells, which are known as a protein production system and can be cultured as a callus.
- the fungal cells include yeasts, for example, the genus Saccharomyces such as Saccharomyces cerevisiae and Saccharomyces pombe; and filamentous bacteria, for example, the genus Aspergillus such as Aspergillus niger.
- bacterial cells include E. coli , for example, JM109, DH5a, and HB101, and Bacillus subtilis .
- the antibodies of the present invention can be prepared in vitro by culturing cells transformed with a DNA of the present invention and purifying the antibodies by conventional methods that are routinely used by those skilled in the art.
- the present invention also provides host organisms that harbor a vector carrying a nucleic acid encoding an antibody of the present invention.
- the host organisms of the present invention are useful in producing recombinant antibodies.
- the host organisms of the present invention include goats.
- transgenic goats of the present invention can be created by the method described below. Specifically, a fusion gene is constructed by inserting an antibody gene in frame within a gene encoding a protein (goat casein or such) intrinsically produced in milk. DNA fragments comprising the fusion gene which contains the inserted antibody gene are injected into goat embryos, and the resulting embryos are introduced into female goats.
- the antibodies of the present invention can be prepared from milk produced by transgenic animals born by the goats that received the embryos, or produced from progenies of these animals. Hormones can be given to the transgenic goats to increase the amount of milk containing the antibodies of the present invention produced by the goats (Ebert, K. M. et al., Bio/Technology 12, 699-702 (1994)).
- the present invention provides imaging agents for visualizing arteriosclerotic sites, which contain an antibody that binds to the oxidized LDL/ ⁇ 2 GPI complex.
- the present invention also provides imaging methods for visualizing arteriosclerotic sites, which comprise a step of administering an antibody of the present invention that binds to the oxidized LDL/ ⁇ 2 GPI complex to mammals.
- the imaging agents of the present invention are administered to mammals to visualize arteriosclerotic sites. Such mammals include humans and nonhuman mammals (for example, mice, rats, hamsters, rabbits, pigs, and monkeys).
- the imaging agents of the present invention are useful in diagnosing arteriosclerosis.
- the imaging agents of the present invention can be used both in vivo and in vitro.
- Arteriosclerotic symptoms are roughly divided into atheroma and calcified lesion. Atheroma sites in arteriosclerosis are especially stained by the imaging agents of the present invention.
- Atheroma is a pathological condition of arteriosclerosis. Macrophages are known to specifically take up via receptor oxidized LDL which contains a large amount of cholesterol, and thereby become foamy. The foamy macrophages accumulate and form plaques (atheromas) on the intima of a blood vessel.
- the imaging agent of the present invention is prepared by linking an imaging label or probe to an antibody that binds to the oxidized LDL/ ⁇ 2 GPI complex, in particular, preferably antibody 3H3.
- the imaging label or probe enables direct or indirect monitoring.
- the distribution or amount accumulated can be assessed using an imagining device such as PET, SPECT, or CCD camera.
- Computer-aided tomography (computed tomography; “CT” also refers to computed tomography) has been applied in a clinical setting such as for disease diagnosis.
- CT computed tomography
- Computer-aided tomography is a technology for generating an image of the interior of an object by scanning the object using a source of penetrating radiation, and processing the data in a computer.
- the CT technology is a technique for obtaining two-dimensional cross sectional patterns of objects (cross sections, etc.) by recording sectional images with positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), or the like.
- PET positron emission tomography
- SPECT single photon emission computed tomography
- MRI magnetic resonance imaging
- These examination techniques are often used not only for obtaining sectional images, but also for presenting three dimensional graphic images by integrating the two-dimensional images using the advanced computer-assisted image processing technology.
- the examination techniques are powerful tools for specifying the three-dimensional location of lesions, diagnosis, decision of operative strategy, and so on.
- enhanced CT refers to CT in which images are taken after a contrast agent or the like having high X-ray absorption is injected into a blood vessel.
- Enhanced CT can be used to observe morphologies of blood vessels and tissues rich in blood flow.
- next-generation CT has been developed, and it can be used alone or in combination to detect the imaging agents of the present invention.
- next-generation CT is not particularly limited, and includes, for example, helical CT in which the irradiation source moves in a spiral manner, and multi-detector computed tomography (MDCT) (also referred to as multi-slice CT (MSCT)) in which detectors are arranged in multiple rows in the direction of body axis.
- MDCT multi-detector computed tomography
- MSCT multi-slice CT
- CT can be used alone as a detector.
- Such labeling substances include, but are not limited to, enzymatic luminescence (luciferase), luminescent low-molecular-weight substances, fluorescent proteins, fluorescent low-molecular-weight substances, and radionuclides.
- radionuclides include, but are not limited to, ⁇ -ray emitting nuclides such as 51 Cr, 59 Fe, 57 Co, 67 Ga, 75 Se, 81m Kr, 99m Tc, 111 In, 125 I, 131 I, 133 Xe, and 201 Tl, and positron-emitting nuclides such as 11 C, 13 N, 15 O, 18 F, 35m Cl, 76 Br, 45 Ti, 48 V, 60 Cu, 61 Cu, 62 Cu, 66 Ga, 89 Zr, 94m Tc, and 124 I, “m” represents nuclear isomer, which is apparent to those skilled in the art.
- indium-111, technetium-99m, and iodine-131 can be particularly preferably used in two-dimensional scanning or single photon emission computed tomography (SPECT).
- Positron-emitting nuclide labels for example, fluoride-19 can be particularly preferably used in positron emission tomography.
- Paramagnetic ions, for example, gadolinium (III) and manganese (II) can be particularly preferably used in magnetic resonance imaging (MRI).
- Such labeling substances include fluorescent labels, those using enzymatic luminescence (luciferase), and those using fluorescence (fluorescent proteins such as GFP, DsRed, and Kusabira Orange; and fluorescent low-molecular-weight substances such as, FITC, Cy5.5, and Alexa Fluor 750).
- labels that have reduced influence from the animal's intrinsic fluorescence are preferred, and labels that emit a signal with high skin permeability are more preferred.
- Magnetic resonance imaging (MRI), PET, and SPECT are used as an imaging detector.
- CCD camera is preferably used as the monitoring device in terms of low invasiveness.
- labels that emit light at a wavelength detectable by CCD camera for example, about 350 to 900 nm, are preferred.
- devices that can be used to determine the intensity of light source inside the body based on values obtained by monitoring the body surface of a test animal with a CCD camera are preferred.
- the image may be a reflection fluorescence image or transmission fluorescence image; however, it is preferable to capture both images.
- the fluorescence images can be observed three-dimensionally by superimposing multi-directionally recorded fluorescence images (regardless of reflection or transmission) and integrating information of the radiation source into the superimposed images. This processing is preferred because it enables reproduction of accurate three-dimensional locations and distribution.
- the three-dimensional images obtained by this method can also be further superimposed with CT images.
- CT can be used alone as the imaging detector (for example, PET or SPECT) as described above, and can also be used to determine the site, accumulated amount, and distribution of arteriosclerotic plaques.
- the labeled probe may be observed by CT alone or in combination with CCD.
- CT is used in combination with CCD, for example, a CCD image of fluorescently labeled probe is superimposed with an image of simple CT (and/or an image of enhanced CT).
- CT images resulting from simple-CT image extraction of organs such as bones and lungs are integrated with fluorescent probe images of major arterial lesions such as in the heart. This enables more accurate understanding of the site, accumulated amount, and distribution of arteriosclerotic plaques, three-dimensional positional relationships relative to tissues and blood vessels, and accurate three-dimensional images (localization) of arteriosclerotic plaques.
- the imaging agents of the present invention can be formulated, in addition to the antibodies, with pharmaceutically acceptable carriers by known methods.
- the agents can be used parenterally, when the antibodies are formulated in a sterile solution or suspension for injection using water or any other pharmaceutically acceptable liquid.
- the agents can be formulated by appropriately combining the antibodies of the present invention with pharmaceutically acceptable carriers or media, specifically, sterile water or physiological saline, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives, binding agents, and such, by mixing them at a unit dose and form required by generally accepted pharmaceutical practices.
- the content of active ingredient in such a formulation is adjusted so as to contain an appropriate dose within the specified range.
- Sterile compositions for injection can be formulated using vehicles such as distilled water for injection, according to standard formulation protocols.
- Aqueous solutions to be used for injection include, for example, physiological saline and isotonic solutions containing glucose or other adjuvants such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride. They may be used in combination with suitable solubilizers such as alcohol, specifically ethanol, polyalcohols such as propylene glycol and polyethylene glycol, and non-ionic surfactants such as Polysorbate 80TM and HCO-50.
- suitable solubilizers such as alcohol, specifically ethanol, polyalcohols such as propylene glycol and polyethylene glycol, and non-ionic surfactants such as Polysorbate 80TM and HCO-50.
- Oils include sesame oils and soybean oils, and can be combined with solubilizers such as benzyl benzoate or benzyl alcohol. They may also be formulated with buffers, for example, phosphate buffer or sodium acetate buffer; analgesics, for example, procaine hydrochloride; stabilizers, for example, benzyl alcohol or phenol; or antioxidants.
- buffers for example, phosphate buffer or sodium acetate buffer
- analgesics for example, procaine hydrochloride
- stabilizers for example, benzyl alcohol or phenol
- antioxidants antioxidants. The prepared injections are typically aliquoted into appropriate ampules.
- the administration is preferably parenteral, and specifically includes injection, intranasal administration, intrapulmonary administration, and percutaneous administration.
- injections can be administered systemically or locally by intravenous injection, intramuscular injection, intraperitoneal injection, or subcutaneous injection.
- the method of administration can be appropriately selected depending on the patient's age and symptoms.
- the dosage of the imaging agents of the present invention can be selected, for example, from the range of 0.0001 to 1,000 mg per kg of body weight for each administration.
- the dosage may be, for example, in the range of 0.001 to 100,000 mg/person.
- the dosage is not limited to these values.
- the dose and method of administration vary depending on the subject's body weight, age, symptoms, and intensity of fluorescent labeling per mg antibody/sensitivity of detection device, and can be appropriately selected by those skilled in the art.
- the present invention also provides imaging kits for visualizing arteriosclerotic sites, which comprise an antibody of the present invention which binds to the oxidized LDL/ ⁇ 2 GPI complex.
- the kits of the present invention visualize arteriosclerotic sites when administered to subjects.
- the above-described kits contain in addition to an antibody of the present invention, for example, injectors (apparatuses for drip infusion), adjuvants for suppressing non-specific adsorption (for example, albumin), and such, without limitation thereto.
- kits may also contain items generally contained in kits, such as instruction manuals, appropriate containers, and control reagents used in imaging.
- the present invention provides methods of screening for candidate compounds as therapeutic agent for treating arteriosclerosis, which comprise the steps of:
- arteriosclerotic plaques for example, the size or site of arteriosclerotic plaques
- Candidate compounds that can be used in the screening methods of the present invention include, but are not limited to, purified proteins (including antibodies), expression products of gene libraries, synthetic peptide libraries, DNA and RNA libraries (including functional nucleic acids such as aptamers and siRNAs), cell extracts, cell culture supernatants, and synthetic low-molecular-weight compound libraries.
- Nonhuman animal models of disease that can be used in the screening methods of the present invention include, but are not limited to, mice, hamsters, rats, rabbits, pigs, and monkeys.
- Arteriosclerosis model mice include, for example, transgenic mice in which a gene is overexpressed, and knockout mice that are deficient in a gene as a result of gene targeting.
- Arteriosclerosis models include, for example, apoE-deficient (apoE ⁇ / ⁇ ) model (apoE (apolipoprotein E) is a protein that forms LDL which is known as bad cholesterol), LDL receptor-deficient (LDLR ⁇ / ⁇ ) model, model introduced with human apoB, and model introduced with dominant apoE mutation.
- Such model mice also include type 2 diabetes model mice (KKAy), and arteriosclerosis model mice which are produced by feeding C57BL6 mice with a high cholesterol diet or such.
- the C57BL6 line is known to have the greatest tendency of developing arteriosclerosis among mice, and mice of this line sometimes show arteriosclerotic plaques by simply feeding on a high cholesterol diet.
- Arteriosclerotic plaques are sometimes seen in rabbits fed a high cholesterol diet for about 2.5 months. Furthermore, LDL receptor-deficient arteriosclerosis model rabbits include WHHL rabbits.
- a pig arteriosclerosis model is also known, which has a tendency to develop arteriosclerosis due to abnormality in the amino acid sequence of the LDL receptor-binding domain of apoB.
- Those skilled in the art can prepare arteriosclerosis model animals by referring to documents such as “Kessensho/Doumyakukoka Model Doubutu Sakuseihou (Methods for producing thrombosis/arteriosclerosis model animals), Ed., Koji Suzuki (Kinpodo)”.
- the resulting model animals can be used in the present invention.
- the present invention provides therapeutic agents for arteriosclerosis, which comprise as an active ingredient a substance selected by the screening methods of the present invention.
- the present invention also relates to the use of compounds selected by the screening methods of the present invention in manufacturing therapeutic agents for arteriosclerosis.
- substances isolated by the screening methods of the present invention are used as a therapeutic agent, they can be used after they are formulated using known pharmaceutical production methods. For example, such substances are administered to patients in combination with pharmaceutically acceptable carriers or media (physiological saline, vegetable oils, emulsifiers, detergents, stabilizers, etc.).
- the substance is administered transdermally, nasally, transbronchially, intramuscularly, intravenously, or orally according to its properties.
- the dosage depends on the patient's age, weight, and symptoms, and the method of administration. However, those skilled in the art can select an appropriate dose.
- SEQ ID NO: 1 the amino acid sequence of heavy-chain variable region
- SEQ ID NO: 6 the amino acid sequence of light-chain variable region
- 0.2 mg/ml oxidized LDL described above was incubated at a final concentration of 0.2 mg/ml with human ⁇ 2 GPI (purchased from Affinity Biologicals) at 37° C. for 16 hours to form the oxidized LDL/ ⁇ 2 GPI complex.
- human ⁇ 2 GPI purchased from Affinity Biologicals
- Purified protein of human oxidized LDL/ ⁇ 2 GPI complex was mixed with the same amount of complete adjuvant (SIGMA; F5881).
- BALB/c mice female were immunized through footpads with the resulting emulsion at 5 to 50 ⁇ g/head every three to seven days several times. Three to five days after the final immunization, inguinal lymph nodes were excised from the mice, and fused with cells of mouse myeloma P3U1 (P3-X63Ag8U1).
- FBS fetal bovine serum
- P3U1 was prepared by culturing in RPMI1640-10% FBS (containing penicillin and streptomycin).
- the precipitated fused cells were appropriately diluted with HAT medium containing 15% FCS(RPMI1640, HAT-supplement (Invitrogen; 11067-030), penicillin, and streptomycin), and plated at 200 ⁇ l/well in 96-well microplates.
- the fused cells were cultured in a CO 2 incubator (5% CO 2 , 37° C.). When the cells were sufficiently grown as colonies, screening was carried out by sampling the culture supernatants.
- clones were selected by ELISA (described in Example 4) using 96-well plates coated with the human oxidized LDL/ ⁇ 2 GPI complex, which was the same as that used as the immunizing antigen.
- the clones were expanded using HT medium (RPMI1640, HT-supplement (Invitrogen; 21060-017), penicillin, and streptomycin) containing 15% FCS, and then cloned into single clones by the limiting dilution method.
- This screening which used the anti-human oxidized LDL/ ⁇ 2 GPI complex antibody as an immunogen yielded seven types of hybridoma clones including clone 3H3.
- the ELISA for detecting an anti-human oxidized LDL/ ⁇ 2 GPI complex antibody was carried out by the method described below. Specifically, 50 ⁇ l of 1 ⁇ g/ml oxidized LDL/ ⁇ 2 GPI was added to each well of microplates (Nunc; Maxisorp). The plates were incubated at 4° C. overnight to adsorb the complex, and then blocked with 1% BSA. Antibody samples were diluted using an assay buffer (1% BSA, 0.15 M NaCl/20 mM HEPES (pH 7.4)) to the antibody concentrations indicated on the horizontal axis. 50 ⁇ l of each sample was added to the wells, and the wells were incubated for 30 minutes.
- an assay buffer 1% BSA, 0.15 M NaCl/20 mM HEPES (pH 7.4)
- ELISA was carried out by the method described below. Specifically, 50 ⁇ l of 1 ⁇ g/ml ⁇ 2 GPI was added to each well of microplates (Nunc; Maxisorp). The plates were incubated at 4° C. overnight to adsorb ⁇ 2 GPI, and then blocked with 1% BSA. Antibody samples were diluted using the assay buffer (1% BSA, 0.15 M NaCl/20 mM HEPES (pH 7.4)) to the antibody concentrations indicated on the horizontal axis. 50 ⁇ l of each sample was added to the wells, and incubated for 30 minutes. The solutions were discarded, and the wells were washed with 0.1% Tween 20/PBS.
- ⁇ 2 GPI up to 50 ⁇ g/ml
- concentrations of ⁇ 2 GPI up to 50 ⁇ g/ml were prepared and added at 50 ⁇ l/well to microplates (Nunc; Maxisorp). The plates were incubated at 4° C. overnight to adsorb ⁇ 2 GPI. Then, the antibody reactivity was tested in the same manner (data not shown).
- ApoE ⁇ / ⁇ mice and LDLR ⁇ / ⁇ mice were fed a common diet (Oriental Yeast NMF) up to eight weeks old, and then fed a high fat diet (common diet additionally containing 1% cholesterol, 1% cholic acid, and 15% salt-free butter) for four to six months.
- a common diet Oriental Yeast NMF
- high fat diet common diet additionally containing 1% cholesterol, 1% cholic acid, and 15% salt-free butter
- the prepared cryosections were fixed with paraformaldehyde and then used in the experiment of fluorescent antibody immunostaining.
- Sections were fixed with 1% paraformaldehyde for five minutes, and then incubated with various monoclonal antibodies at 4° C. overnight. After washing, the sections were incubated with an FITC-labeled anti-mouse IgG or IgM antibody (secondary antibody) at room temperature for one hour. Staining with DAPI and Rhodamine Phalloidin was carried out by addition with the secondary antibody at the time of incubation. Then, the sections were observed and photographed under a fluorescent microscope.
- Fluorescent immunostaining of the aortic valve in arteriosclerosis-prone model mice was compared to the result obtained using different antibodies that recognize the oxidized LDL/ ⁇ 2 GPI complex.
- Antibodies positive for atheroma in the staining were only antibodies 3H3 and A ( FIG. 5 ).
- the present invention enables arteriosclerotic plaque-specific immunostaining using various atheroma-specific monoclonal antibodies labeled with Cy5.5, Alexa, or the like.
- Imaging was performed using IVISTM Imaging System, IVIS 200, from Xenogen (excitation, 640 nm; emission, 720 nm).
- the fluorescence intensity was determined per unit area of the aortic root.
- the fluorescence of PBS-administered control mouse was taken as 1.0. When 3H3 was administered, fluorescence was three times stronger than the control. There was no significant change in the fluorescence intensity when other antibodies were administered ( FIG. 10 ).
- ⁇ 2 GPI was added as an inhibitory, competitive antigen to the immobilized oxidized LDL/ ⁇ 2 GPI complex or immobilized ⁇ 2 GPI, and the resulting inhibition was assessed by ELISA.
- the result is as follows: in the case of immobilized oxidized LDL/ ⁇ 2 GPI complex, 3D4>2H6>4C12>3H3; and in the case of immobilized ⁇ 2 GPI, 2H6>3D4 (4C12 and 3H3 bound only weakly to immobilized ⁇ 2 GPI).
- 3H3 was highly specific to the free (non-denatured) form of oxidized LDL/ ⁇ 2 GPI complex in a solution.
- the antibody subclasses of the four clones are as follows: 3H3 and 4C12 are IgG2b; and 2H6 and 3D4 are IgG1.
- Hybridomas which produce four types of monoclonal antibodies were each cultured in RPMI1640 supplemented with 10% FCS.
- mRNAs were obtained from the hybridomas using the QuickPrep micro mRNA purification kit (Amersham Biosciences; code 27-9255-01).
- the mRNAs were converted into cDNAs using the First-Strand cDNA Synthesis kit (Amersham Biosciences; code 27-9261-01).
- Gene amplification was achieved by PCR using the cDNAs as a template. PCR was carried out using the 11 types of primer combinations listed below.
- the sequences of primers MKV1 to MKV11 were designed by analyzing the signal sequences of numerous various monoclonal antibodies.
- the 11 types of primer sequences can cover the L chain signal of almost every monoclonal antibody.
- An L-chain variable region of interest is amplified by using at least a single PCR pattern selected from 11 PCR patterns using combinations of the 11 types of MKV primers with primer MKC which corresponds to the sequence of a mouse L-chain constant region.
- MKV1 primer ATGAAGTTGCCTGTTAGGCTGTTGGTGCTG
- MKV2 primer ATGGAGWCAGACACACTCCTGYTATGGGTG
- MKV3 primer ATGAGTGTGCTCACTCAGGTCCTGGSGTTG
- MKV4 primer ATGAGGRCCCCTGCTCAGWTTYTTGGMWTCTTG
- MKV5 primer ATGGATTTWCAGGTGCAGATTWTCAGCTTC
- MKV6 primer ATGAGGTKCYYTGYTSAGYTYCTGRGG (SEQ ID NO: 17)
- MKV7 primer ATGGGCWTCAAGATGGAGTCACAKWYYCWGG
- MKV8 primer ATGTGGGGAYCTKTTTYCMMTTTTTCAATTG
- MKV9 primer ATGGTR
- Combinations of PCR primers responsible for the amplification of each L-chain variable region by PCR are as follows:
- the L-chain variable region genes amplified by PCR were inserted into pCR2.1 vector (Invitrogen).
- the DNA nucleotide sequence of PCR2.1 vector inserted with an L-chain variable region gene was determined using a DNA sequencer (Applied Biosystems; 3130 Genetic Analyzer).
- Hybridomas which produce four types of monoclonal antibodies were each cultured in RPMI1640 supplemented with 10% FCS.
- mRNAs were obtained from the hybridomas using the QuickPrep micro mRNA purification kit (Amersham Biosciences; code 27-9255-01).
- the mRNAs were converted into cDNAs using the First-Strand cDNA Synthesis kit (Amersham Biosciences; code 27-9261-01).
- Amplification of H chain variable region genes was achieved by PCR using the cDNAs as a template. PCR was carried out using the 12 types of primer combination listed below.
- the sequences of primers MHV1 to MHV12 were designed by analyzing the signal sequences of numerous various monoclonal antibodies. Thus, the 12 types of primer sequences can cover the H chain signal of almost every monoclonal antibody.
- An H-chain variable region of interest is amplified by using at least a single PCR pattern selected from 12 PCR patterns using combinations of the 12 types of MHV primers with primer MHCG2b or MHCG1 which corresponds to the sequence of a mouse H-chain constant region.
- Primer MHCG2b corresponds to the sequence of an H-chain constant region of mouse IgG2b
- primer MHCG1 corresponds to the sequence of an H-chain constant region of mouse IgG1.
- primer MHCG2b was used in the PCR amplification of clones 3H3 and 4C12, which are of the IgG2b subclass.
- Primer MHCG1 was used in the PCR amplification of clones 2H6 and 3D4, which are of the IgG1 subclass.
- the H-chain variable region genes amplified by PCR were inserted into the pCR2.1 vector (Invitrogen).
- the DNA nucleotide sequence of the PCR2.1 vector inserted with an H-chain variable region gene was determined using a DNA sequencer (Applied Biosystems; 3130 Genetic Analyzer).
- amino acid sequence of 3H3 and its CDRs were revealed, and can be used in the present invention ( FIG. 11 ).
- amino acid and nucleotide sequences of the antibodies of the present invention are shown in the Sequence Listing according to the following SEQ IDs shown below.
- SEQ ID NO: 1 the amino acid sequence of heavy-chain variable region
- SEQ ID NO: 6 the amino acid sequence of light-chain variable region
- Fluorescence imaging was carried out using IVIS 200 Imaging System (Xenogen) (for Cy5.5, [excitation, 640 nm; emission, 720 nm]; for Alexa Fluor 750, [excitation, 745 nm; emission, 800 nm]).
- 0.25 mg/ml Cy5.5-labeled antibody 3H3 (IgG) or 1.0 to 1.5 mg/ml Alexa Fluor 750-labeled antibody 3H3 was administered at 0.15 ml/head via the caudal vein to ApoE ⁇ / ⁇ mice fed a high fat diet, and after two to 24 hours under inhalation anesthesia, in vivo fluorescence was observed and photographed using IVIS 200.
- mice were observed after shaving, because their black hair absorbs fluorescence. First, the fluorescence was observed with reflected light, and then with transmitted light. Three-dimensional (3D) images of mice were generated and integrated with the light source information ( FIG. 9A : a three-dimensional image by IVIS before integration). In the figure, red dots correspond to fluorescent signals from labels linked to 3H3. The denser red dots mean stronger fluorescence intensity, showing the localization of the imaging agent.
- mice were euthanized, and the hearts were perfused with 10 ml of PBS.
- the hearts and aortae were excised and their reflection fluorescence images were obtained using IVIS 200.
- CT imaging was performed using eXplore Locus CT System (GE Healthcare). Under inhalation anesthesia, the same mice used in the IVIS 200 imaging were irradiated with X ray to obtain CT images.
- FIG. 9B a three-dimensional CT image after integration
- the procedure is shown schematically ( FIG. 8 ).
- (C) Image resulting from integration of IVIS fluorescent signal and three-dimensional CT image the photograph shows a three-dimensional image generated as animation in a computer-generated virtual space (three-dimensional graphic animation). The sites labeled were observed from multiple angles.
- near-infrared fluorescent labels are suitable for in vivo imaging.
- antibodies labeled with Cy5.5 or Alexa Fluor 750 were administered to mice via the caudal vein, and the resulting fluorescence was monitored with IVIS 200 to assess the measurement conditions for the reflection and transmission fluorescence.
- ApoE ⁇ / ⁇ mice with arteriosclerosis were observed by in vivo reflection fluorescence imaging using a Cy5.5-labeled antibody, intense signals were found in the aortic valve and thoracic aorta.
- FIG. 8B middle panel
- FIG. 8B right panel
- FIG. 8B shows that the presence of fluorescent signals in and around the heart.
- the denser red dots suggest stronger fluorescence intensity, showing the localization of the imaging agent.
- CT image (middle panel) and 3D-CT integrated image ( FIG. 8B , right panel) are shown.
- a three-dimensional image was generated as animation in a computer-generated virtual space (three-dimensional graphic animation). The sites labeled were observed from multiple angles ( FIG. 8C ).
- the sites (locations) of arteriosclerosis cannot be identified by conventional tests for arteriosclerosis.
- the present invention provides non-invasive diagnostic methods that allow visual identification of the site and size of arteriosclerotic plaques (in particular, atheroma and atherosclerosis).
- a screening system for therapeutic agents to treat atherosclerosis can be constructed by using arteriosclerosis-prone model mice (for example, apoE-deficient (ApoE ⁇ / ⁇ ) mice; which maintain high plasma cholesterol level, and spontaneously develop an atherosclerosis-like condition) and antibodies for the imaging.
- arteriosclerosis-prone model mice for example, apoE-deficient (ApoE ⁇ / ⁇ ) mice; which maintain high plasma cholesterol level, and spontaneously develop an atherosclerosis-like condition
- an imaging system for clinical diagnosis can be constructed by converting the antibodies into humanized antibodies.
- plaques or such detached from atheroma lesions of arteries are known to cause arterial embolism which leads to cerebral embolism or myocardial infarction.
- Methods for monitoring human arthrosclerosis which progresses insidiously, asymptomatically, and chronically can be expected to benefit strategies for preventing or treating lifestyle-related diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
- The present invention relates to antibodies against an oxidized LDL/β2GPI complex, and non-invasive diagnostic methods for arteriosclerosis using the antibodies such as methods for identifying atherosclerotic lesion sites and methods for monitoring the therapeutic effects.
- Diagnostic methods for assessing the condition of arteriosclerosis, which have already been put to practical use, include, for example, the four methods described below.
- “Ankle-brachial pressure index”: When blood pressure is measured at the arm and ankle levels in the supine position, the ankle blood pressure is normally slightly higher. However, the narrowing of a blood vessel reduces the downstream blood pressure, which results in a decrease in the ratio of ankle blood pressure to brachial blood pressure (ABI). A decrease in ABI not only indicates arteriosclerosis in the artery of the lower limb but also suggests systemic arteriosclerosis.
- “Pulse wave velocity test”: A method for estimating the progression of arteriosclerosis by assessing arterial stiffness. In healthy individuals, blood vessels are elastic and thus vascular walls absorb vibration, resulting in a reduction in pulse wave velocity. As arteriosclerosis advances, the wave velocity increases. Thus, the progression of arteriosclerosis can be estimated using the velocity as an indicator.
- “Carotid ultrasound examination”: A method for estimating the progression of systemic arteriosclerosis by observing carotid arteries which run very close to the surface of skin and have an interior condition that is easy to observe by ultrasound.
- “MR angiography (MRA)” and “CT angiography (CTA)”: Angiography was used as a major diagnostic imaging method for vascular diseases, but image information that is almost comparable to angiography but obtained in a less invasive manner has become available. The advantages of CTA include: (1) high spatial resolution; (2) simple examination; and (3) superiority in detecting calcified lesions.
- The above-described “ankle-brachial pressure index” and “pulse wave velocity test” can neither identify the site of atherosclerosis nor diagnose the progression at each site. Thus, these methods only provide indirect scores to assess arteriosclerosis.
- Unlike pulse wave velocity test or such, “carotid ultrasound examination” is superior in that it enables direct graphical observation of the inside of blood vessels. However, the condition of vascular wall is assessed based on the contrasting density and shape in ultrasonic images, and thus clinicians and laboratory technicians who conduct the test are required to have skills. Furthermore, the test cannot identify the site of atherosclerosis or diagnose the progression at individual sites in blood vessels other than the carotid artery.
- Meanwhile, methods for monitoring the progression of arteriosclerosis include ELISA systems for measuring the oxidized LDL/β2GPI complex in blood (Japanese Patent Nos. 3370334 and 3898680; WO2003/022866, WO2004/023141). However, conventional ELISA for measuring the oxidized LDL/β2GPI complex can be used to estimate the size but not the site of atherosclerotic plaque.
- Meanwhile, even when MRI or radiolabeled imaging is used, the condition of vascular wall is assessed based on the contrasting densities and shapes in ultrasonic images, and thus clinicians and laboratory technicians who conduct the test are required to have skills and expertise (U.S. Pat. Nos. 6,716,410 and 6,375,925).
- Prior art documents related to the present invention include:
- [Patent Document 1] Japanese Patent No. 3370334
- [Patent Document 2] Japanese Patent No. 3898680
- [Patent Document 3] WO 2003/022866
- [Patent Document 4] WO 2004/023141
- [Patent Document 5] Japanese Patent Application Kohyo Publication No. (JP-A) 2001-506983 (unexamined Japanese national phase publication corresponding to a non-Japanese international publication)
- [Patent Document 6] Japanese Patent No. 4044972
- [Patent Document 7] U.S. Pat. No. 6,716,410
- [Patent Document 8] U.S. Pat. No. 6,375,925
- [Non-patent Document 1] Journal of Biological Chemistry 269, 15274-15279, 1994
- An objective of the present invention is to provide antibodies against an oxidized LDL/β2GPI complex, and non-invasive diagnostic methods for arteriosclerosis using the antibodies such as methods for identifying arteriosclerosis lesion sites and methods for monitoring the therapeutic effects.
- From antibodies that can be used to immunostain atherosclerotic tissue sections, the present inventors selected antibodies applicable to in vivo imaging, specifically to visualize atherosclerotic plaques, in particular, the location and size of atheroma in the body. Then, the prevent inventors analyzed the specificities of the antibodies. The result showed that fluorescently labeled anti-oxidized LDL/β2GPI complex antibodies that are specific to a particular epitope were effective for imaging.
- Specifically, the present invention provides:
- [1] an antibody of any one of (a) to (e) below, which binds to a complex of oxidized LDL and β2-glycoprotein I (oxidized LDL/β2GPI complex):
- (a) an antibody comprising a heavy chain that comprises CDR1 having the amino acid sequence of SEQ ID NO: 2, CDR2 having the amino acid sequence of SEQ ID NO: 3, and CDR3 having the amino acid sequence of SEQ ID NO: 4;
- (b) an antibody comprising a heavy chain that comprises a heavy-chain variable region having the amino acid sequence of SEQ ID NO: 1;
- (c) an antibody comprising a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO: 7, CDR2 having the amino acid sequence of SEQ ID NO: 8, and CDR3 having the amino acid sequence of SEQ ID NO: 9;
- (d) an antibody comprising a light chain that comprises a light-chain variable region having the amino acid sequence of SEQ ID NO: 6; and
- (e) an antibody that comprises a pair of the heavy chain of (a) or (b) above and the light chain of (c) or (d) above;
- [2] an antibody that binds to the same epitope as the antibody of any one of [1];
[3] the antibody of [1] or [2], which is a humanized or chimeric antibody;
[4] an imaging agent for visualizing an arteriosclerosis site, which comprises an antibody that binds to a complex of oxidized LDL and β2-glycoprotein I (oxidized LDL/β2GPI complex);
[5] an imaging agent for visualizing an arteriosclerosis site, which comprises the antibody of any one of [1] to [3];
[6] the imaging agent of [4] or [5], for determining the location and/or size of atheroma in arteriosclerosis;
[7] an imaging kit for visualizing an arteriosclerosis site, which comprises an antibody that binds to a complex of oxidized LDL and β2-glycoprotein I (oxidized LDL/β2GPI complex);
[8] an imaging kit for visualizing an arteriosclerosis site, which comprises the antibody of any one of [1] to [3];
[9] a method of screening for a candidate compound for a therapeutic agent for arteriosclerosis, which comprises the steps of: - (a) administering a candidate compound to an arteriosclerosis model nonhuman animal administered with the antibody of any one of [1] to [3];
- (b) carrying out imaging of an arteriosclerotic plaque in an arteriosclerosis model nonhuman animal administered with the candidate compound and in an arteriosclerosis model nonhuman animal not administered with the candidate compound;
- (c) comparing the size or location of an arteriosclerotic plaque between the arteriosclerosis model nonhuman animal administered with the candidate compound and the arteriosclerosis model nonhuman animal not administered with the candidate compound; and
- (d) selecting a candidate compound that reduces or eliminates an arteriosclerotic plaque in the arteriosclerosis model nonhuman animal administered with the candidate compound as compared to the arteriosclerosis model nonhuman animal not administered with the candidate compound;
- [10] an imaging agent for visualizing an arteriosclerosis site, which comprises the antibody of any one of [1] to [3];
[11] use of the antibody of any one of [1] to [3] for the manufacture of an imaging agent for visualizing an arteriosclerosis site; and
[12] the antibody of any one of [1] to [3] for use in an imaging method for visualizing an arteriosclerosis site. -
FIG. 1 is diagrams showing antibody reactivities to immobilized antigen. The antibodies were monoclonal antibodies obtained by immunizing BALB/c mice with the oxidized LDL/β2GPI complex as an antigen. The horizontal axis indicates antibody concentration, and the vertical axis indicates the absorbance. -
FIG. 2 is a diagram for assaying competitive nature of antigen in solution (competitive inhibition assay). -
FIG. 3 is graphs showing a test of competitive inhibition by antigen. The horizontal axis indicates antigen concentration in a liquid, and the vertical axis indicates the percent inhibition (%) determined when taking the absorbance in the absence of inhibitory antigen as 100%. 3H3 and 4C12 are antibodies that recognize β2GPI bound to oxidized LDL. These antibodies do not recognize free β2GPI. 2H6, 3D4, and 2A12 are antibodies reactive to free β2GPI. -
FIG. 4 is photographs showing fluorescent immunostaining of the aortic valve in arteriosclerosis-prone model mice (apoE−/− fed a high fat diet). (A) DAPI, nuclear stain; (B) Mac3, macrophage-specific antibody; (C), antibody 3H3; (D), control. When used in fluorescent immunostaining of C57BL6 mice fed a normal diet, Mac3 stained atheroma formed via accumulation of foamy macrophages. 3H3 stained the same areas. -
FIG. 5 is photographs showing fluorescent immunostaining of the aortic valve in arteriosclerosis-prone model mice (apoE−/− fed a high fat diet). The photographs show results of fluorescent immunostaining using other antibodies against the oxidized LDL/β2GPI complex. Antibodies positive for atheroma in the staining were only antibodies 3H3 and A. -
FIG. 6 is photographs showing IVIS 200 fluorescence imaging using specific antibody (reflection fluorescence microscopy). In vivo: ApoE−/− mice were fed a high fat diet for six months or more. Imaging agents were administered to the mice at the caudal vein. After two to 24 hours, in vivo fluorescence was observed and photographed under inhalation anesthesia using IVIS 200. The ApoE−/− mice were observed after shaving, because their black hair absorbs fluorescence. Ex vivo: Mice euthanized were thoracotomized. The heart and aorta were exposed, and a small incision was made in the right auricular appendage. Then, a needle was inserted into the left ventricle and the heart was perfused with 10 ml of cold PBS. The heart and aorta were excised and their reflection fluorescence microscopic images were recorded using IVIS 200. -
FIG. 7 is photographs showing IVIS 200 fluorescence imaging (excitation, 640 nm; emission, 720 nm). Experiment 1: physiological saline (PBS; control), Cy5.5-labeled antibody A, or Cy5.5-labeled antibody 3H3 was administered at the caudal vein to apoE−/− mice fed a high fat diet. Twenty four hours after administration, the mice were photographed alive for the full-body image after removing their thoracic skin. Then, the heart intact with thoracic aorta was excised and photographed. Experiment 2: Hearts and aortae excised from mice administered with PBS, Cy5.5-labeled antibody 2A12, or y5.5-labeled antibody 3H3. Administered 3H3 intensely stained the aortic root. Antibody A also stained to some extent; however, the fluorescence intensity is weaker as compared to 3H3. There was no stain in the case of 2A12. -
FIG. 8 is photographs showing three-dimensional imaging of arteriosclerosis using the specific antibody. (A), IVIS 200 fluorescence imaging using the specific antibody (reflection fluorescence microscopy); (B), IVIS 200 3D image obtained using transmitted light (left panel), CT 3D image before superimposing (middle panel), and the superimposed 3D image (right panel); (C) superimposed 3D images generated from IVIS fluorescence signal and 3D CT. -
FIG. 9 is photographs showing IVIS 200 fluorescence three-dimensional images before superimposing (upper panels, A) and superimposed images generated from IVIS 200 fluorescence signal and 3D CT (bottom panels, B). -
FIG. 10 is a diagram showing fluorescence intensity of Cy5.5 around the aortic root observed using IVIS 200. The fluorescence intensity was determined per unit area of the aortic root. The fluorescence of PBS-administered control mouse was taken as 1.0. When 3H3 was administered, fluorescence was three times stronger than the control. When other antibodies were administered, there was no significant change in the fluorescence intensity. -
FIG. 11 is a diagram showing the amino acid sequence of antibody 3H3. Each CDR is underlined. - The present invention provides antibodies that bind to a complex of oxidatively modified LDL (oxidized LDL) and β2-glycoprotein I (oxidized LDL/β2GPI complex). The complex is formed between oxidized LDL and β2GP in atherosclerotic plaques. β2GP is a serum glycoprotein. The antibodies of the present invention bind to the complex.
- Specifically, the antibodies of the present invention include those described below, but are not limited thereto:
- (a) an antibody comprising a heavy chain that comprises CDR1 having the amino acid sequence of SEQ ID NO: 2, CDR2 having the amino acid sequence of SEQ ID NO: 3, and CDR3 having the amino acid sequence of SEQ ID NO: 4;
- (b) an antibody comprising a heavy chain that comprises a heavy-chain variable region having the amino acid sequence of SEQ ID NO: 1;
- (c) an antibody comprising a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO: 7, CDR2 having the amino acid sequence of SEQ ID NO: 8, and CDR3 having the amino acid sequence of SEQ ID NO: 9;
- (d) an antibody comprising a light chain that comprises a light-chain variable region having the amino acid sequence of SEQ ID NO: 6; and
- (e) an antibody comprising a pair of the heavy chain of (a) or (b) above and the light chain (c) or (d) above.
- The present invention also provides antibodies that bind to the same epitope as an antibody of the present invention that binds to the complex of oxidized LDL and β2-glycoprotein I (oxidized LDL/β2GPI complex). Such antibodies recognize a particular epitope on the oxidized LDL/β2GPI molecule which is a complex formed with oxidized LDL.
- Whether an antibody recognizes the same epitope as another antibody can be confirmed, for example, by their competition for the epitope, although the test method is not limited thereto. The competition between antibodies can be assessed by competitive binding assays. The method includes ELISA, fluorescence resonance energy transfer (FRET), and fluorometric microvolume assay technology (FMAT™). The amount of a particular antibody bound to antigen is indirectly correlated with the binding activity of a competitor antibody candidate (test antibody), which competes for the binding to the same epitope. Specifically, as the amount or affinity of a test antibody for the same epitope increases, the amount of an antibody bound to the antigen decreases, and the amount of test antibody bound to the antigen increases. More specifically, an appropriately labeled antibody is added to the antigen together with a test antibody, and then the bound antibody is detected using the label. The amount of an antibody bound to the antigen can be readily determined by labeling the antibody in advance. Such labels are not particularly limited; however, appropriate labeling methods are selected depending on the technique. Such labeling methods include, for example, fluorescent labeling, radiolabeling, and enzyme labeling.
- Herein, “antibody that recognizes the same epitope” refers to an antibody that can reduce the amount of labeled antibody bound by at least 50%, when a test antibody is used at a concentration typically 100 times higher, preferably 80 times higher, more preferably 50 times higher, even preferably 30 times higher, and still preferably 10 times higher than the IC50 of the non-labeled antibody, where IC50 is defined as a concentration of a non-labeled antibody at which the amount of the labeled antibody bound is decreased by 50% due to the binding of the non-labeled antibody.
- The antibodies of the present invention include both polyclonal and monoclonal antibodies. Methods for preparing and purifying monoclonal and polyclonal antibodies are known in the field, and described, for example, in “Harlow and Lane, Antibodies: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1988)”.
- The antibodies of the present invention also include recombinant antibodies such as humanized antibodies and chimeric antibodies. “Humanized antibody” refers to an antibody whose structure is similar to that of a human antibody. Such humanized antibodies and chimeric antibodies include human-type chimeric antibodies (for example, antibodies in which some portions have been humanized, antibodies whose CH2 region has been humanized, antibodies whose Fc domain has been humanized, antibodies whose constant region has been humanized), CDR-grafted humanized antibodies whose constant and variable regions have been humanized except their complementarity determining regions (CDRs) (P. T. Johons et al., Nature 321, 522 (1986)), and completely humanized antibodies. Improvement methods for enhancing the antigen binding activity of a CDR-grafted human-type antibody have been developed, which include: methods for selecting human antibody FRs that are highly homologous to the mouse antibody, methods for producing highly homologous humanized antibodies, and methods for substituting amino acids in FR after grafting mouse CDRs to human antibodies (see U.S. Pat. Nos. 5,585,089, 5,693,761, 5,693,762, and 6180370; EP Nos. 451216 and 682040; Japanese Patent No. 2828340). Such methods can be used to prepare CDR-grafted human-type antibodies of the present invention.
- Human-type chimeric antibodies can be produced, for example, by substituting a human anybody constant region for the constant region of an above-described antibody having the structure of an H-chain variable region and/or the structure of an L-chain variable region described above. Such human antibody constant regions include known human antibody constant regions. A method for producing human-type chimeric antibodies is described below as an example.
- First, mRNA is extracted from hybridomas producing a mouse antibody against a particular target antigen. cDNA is synthesized from the mRNA by a conventional method. The synthesized cDNA is inserted into a vector to construct a cDNA library. A vector carrying H-chain and L-chain genes is selected from the cDNA library using H-chain gene and L-chain gene fragments as a probe. The sequences of the H-chain variable region and L-chain variable region genes are determined by sequencing the insert in the selected vector. DNA encoding the H-chain variable region is constructed based on the sequence data obtained as described above by chemical synthesis, biochemical cleavage/ligation, or the like. The resulting DNA that encodes the H-chain variable region is ligated with a DNA encoding human H-chain constant region, and then inserted into an expression vector to construct an expression vector for H chain. Such expression vectors include, for example, SV40 virus-based vectors, EB virus-based vectors, and papilloma virus (BPV)-based vectors, but are not limited thereto. Furthermore, expression vectors for L chain are constructed by the same method. Host cells are co-transformed with the H-chain expression vectors and L-chain expression vectors. Preferred host cells include CHO cells (Chinese hamster ovary) (A. Wright & S. L. Morrison, J. Immunol. 160, 3393-3402 (1998)) and SP2/0 cells (mouse myeloma) (K. Motmans et al., Eur. J. Cancer Prey. 5, 512-519 (1996); R. P. Junghans et al., Cancer Res. 50, 1495-1502 (1990)). Transformation can be preferably carried out by using electroporation, a lipofectin method (R. W. Malone et al., Proc. Natl. Acad. Sci. USA 86, 6077 (1989); P. L. Feigner et al., Proc. Natl. Acad. Sci. USA 84, 7413 (1987)), calcium phosphate method (F. L. Graham & A. J. van der Eb, Virology 52, 456-467 (1973)), DEAE-Dextran method, and the like.
- The transformants are cultured, and then human-type chimeric antibodies are isolated from the transformants or culture media. Antibodies can be isolated or purified by an appropriate combination of methods such as centrifugation, ammonium sulfate fractionation, salting out, ultrafiltration, affinity chromatography, ion exchange chromatography, and gel filtration chromatography.
- Meanwhile, human-type CDR-grafted antibodies can be produced, for example, by the following method. First, the amino acid sequences of H-chain and L-chain variable regions of an antibody against a particular antigen, and nucleotide sequences encoding them are determined by the methods for producing chimeric antibodies as described above. The amino acid and nucleotide sequences of each CDR are determined as well.
- Next, framework regions (FRs) which sandwich CDRs are selected. Three methods are available for selecting FRs. The first method uses human antibody frames with known three dimensional structures, such as NEWM and REI (Riechmann L. et al., Nature 332, 323-3Z7 (1988); Tempst, P R. et al., Protein Engineering 7, 1501-1507 (1994); Ellis J H. et al., J. Immunol 155, 925-937 (1995)). The second method uses FRs of a human antibody variable region that is most homologous to a mouse antibody variable region of interest, in which the human antibody variable region is selected from databases (Queen C. et al., Proc Natl Acad Sci USA 86, 10029-10033 (1989); Rozak M J. et al., J Biol Chem 271, 22611-22618 (1996); Shearman C W. et al., J. Immunol 147, 4366-4373 (1991)). In the third method, amino acids most commonly shared by human antibody FRs are selected (Sato K. et al., Mol Immunol 31, 371-381 (1994); Kobinger F. et al.,
Protein Engineering 6, 971-980 (1993); Kettleborough C A. et al.,Protein Engineering 4, 773-783 (1991)). All of these methods can be used in the present invention. - Furthermore, FR amino acid sequences to be used also include amino acid sequences resulting from modification of the amino acid sequence of a selected human FR, as long as the human-type CDR-grafted antibody produced from it has the activity of specifically binding to the target antigen. In particular, when a portion of the amino acid sequence of a selected human FR is replaced with the amino acid sequence of an FR of the antibody from which CDR is derived, the resulting antibody is very likely to retain the antibody properties. The number of amino acids to be modified is preferably 30% or less in a whole FR, more preferably 20% or less in a whole FR, and still more preferably 10% or less in a whole FR.
- Next, DNAs encoding H-chain and L-chain variable regions are designed by combining the above-described CDRs with FRs selected by any one of the methods described above. Based on this design, DNAs encoding H-chain variable regions and DNAs encoding L-chain variable regions are prepared by chemical synthesis, biochemical cleavage/ligation, or the like. Then, an H-chain expression vector is constructed by inserting into an expression vector the H-chain variable region-encoding DNA, along with a DNA encoding an H-chain constant region of human immunoglobulin. Likewise, an L-chain expression vector is constructed by inserting into an expression vector the L-chain variable region-encoding DNA, along with a DNA encoding an L-chain constant region of human immunoglobulin. Expression vectors include, for example, SV40 virus-based vectors, EB virus-based vectors, and papilloma virus (BPV)-based vectors, but are not limited thereto.
- Host cells are co-transformed with the H-chain expression vectors and L-chain expression vectors prepared by the method described above. Such preferred host cells include CHO cells (Chinese hamster ovary) (A. Wright & S. L. Morrison, J. Immunol. 160, 3393-3402 (1998)) and SP2/0 cells (mouse myeloma) (K. Motmans et al., Eur. J. Cancer Prev. 5, 512-519 (1996); R. P. Junghans et al., Cancer Res. 50, 1495-1502 (1990)). Transformation can be preferably carried out by using electroporation, a lipofectin method (R. W. Malone et al., Proc. Natl. Acad. Sci. USA 86, 6077 (1989); P. L. Feigner et al., Proc. Natl. Acad. Sci. USA 84, 7413 (1987)), calcium phosphate method (F. L. Graham & A. J. van der Eb, Virology 52, 456-467 (1973)), DEAE-Dextran method, and the like.
- The transformants are cultured, and then human-type CDR-grafted antibodies are isolated from the transformants or culture media. Antibodies can be isolated or purified by an appropriate combination of methods such as centrifugation, ammonium sulfate fractionation, salting out, ultrafiltration, affinity chromatography, ion exchange chromatography, and gel filtration chromatography.
- Methods for preparing human antibodies are also known. For example, desired human antibodies with antigen-binding activity can be obtained by sensitizing human lymphocytes in vitro with an antigen of interest or cells expressing an antigen of interest; and fusing the sensitized lymphocytes with human myeloma cells such as U266 (see Japanese Patent Application Kokoku Publication No. (JP-B) H01-59878 (examined, approved Japanese patent application published for opposition)). Alternatively, desired human antibodies can also be obtained by using an antigen of interest to immunize transgenic animals that have the entire repertoire of human antibody genes (see International Patent Application WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, and WO 96/33735).
- In an alternative embodiment, antibodies and antibody fragments can be isolated from an antibody phage library produced by using the technique described by McCafferty et al. (Nature, 348: 552-554 (1990)). Clackson et al. (Nature, 352: 624-628 (1991)) and Marks et al. (J. Mol. Biol., 222: 581-597 (1991)) reported isolation of mouse and human antibodies using phage libraries. Subsequently published documents describe generation of high-affinity (nM range) human antibodies by chain shuffling (Marks et al., Bio/Technology, 10: 779-783 (1992)); and combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries (Waterhouse et al., Nuc. Acids. Res., 21: 2265-2266 (1993)). These techniques can serve as an alternative method for isolating monoclonal antibodies, which are used instead of the conventional hybridoma method for preparing monoclonal antibodies.
- In this context, the bacteriophage (phage) display is one of the well-known techniques that enable one to search a large oligopeptide library and identify library members having the ability to specifically bind to a target polypeptide. The phage display is a technique that displays various polypeptides as a fusion protein with the coat protein on the surface of bacteriophage particles (Scott, J. K. and Smith G. P. Science 249: 386 (1990)). An advantage of phage display is that it enables rapid and effective categorization of a large library of selectively randomized protein mutants (or random cDNA clones) for the sequences that bind with high affinity to a target molecule. The phage display of peptide library (Cwirla, S. E. et al., Proc. Natl. Acad. Sci. USA, 87: 6378 (1990)) or protein library (Lowman, H. B. et al., Biochemistry, 30: 10832 (1991); Clackson, T. et al., Nature, 352:624 (1991); Marks, J. D. et al., J. Mol. Biol., 222: 581 (1991); Kang, A. S. et al., Proc. Natl. Acad. Sci. USA, 88:8363 (1991)) has been used to screen a vast number of oligopeptides or polypeptides for those that have a specific binding property (Smith, G P. Current Opin. Biotechnol., 2:668 (1991)). Categorization in a phage library of random mutants requires a method for constructing and propagating a vast number of mutants; an affinity purification method using a target receptor; and a method for assessing the enhanced binding (see U.S. Pat. Nos. 5,223,409, 5,403,484, 5,571,689, and 5663143).
- Most phage display methods use filamentous phages; however, known phage display methods also include λ phage display system (WO 95/34683; U.S. Pat. No. 5,627,024), T4 phage display system (Ren J. et al., Gene 215: 439 (1998); Zhu et al., Cancer Research, 58 (15):3209-3214 (1998); Jiang et al., Infection & Immunity, 65(11): 4770-4777 (1997); Ren et al., Gene, 195(2): 303-311 (1997); Ren, Protein Sci. 5: 1833 (1996); Efimov et al., Virus Genes 10: 173 (1995)) and T7 phage display system (Smith and Scott, Methods in Enzymology, 217, 228-257 (1993); U.S. Pat. No. 5,766,905).
- To date, there are many improved and modified methods developed based on the basic phage display method. These modifications have improved the methods for screening peptide or protein libraries based on a property or ability such as the activity of binding to a selected target molecule. Recombination means for the phage display method are described in WO 98/14277. Phage display libraries have been used to analyze and control bimolecular interactions (WO 98/20169; WO 98/20159) and properties of constrained helical peptide (WO 98/20036). WO 97/35196 describes a method for isolating affinity ligands, in which bound ligands are selectively isolated by contacting a phage display library with a first solution that allows binding of the ligand to a target molecule and then with a second solution where affinity ligand does not bind to the target molecule. WO 97/46251 describes a method for isolating high affinity-binding phages in which a random phage display library is treated by biopanning using an affinity-purified antibody, followed by isolation of bound phages, and then by micropanning in the wells of microplates. There is also a report published on the use of Staphylococcus aureus protein A as an affinity tag (Li et al., Mol. Biotech., 9: 187 (1998)). WO 97/47314 describes the use of substrate subtraction library in identifying enzymatic specificity using a combinatorial library which may be a phage display library. WO 97/09446 describes a method for selecting enzymes that are suitable as a washing reagent to be used in phage display. Other methods for selecting proteins that bind in a specific manner are described in U.S. Pat. Nos. 5,498,538 and 5,432,018, and WO 98/15833. Methods for constructing and screening peptide libraries are described in U.S. Pat. Nos. 5,723,286, 5,432,018, 5,580,717, 5,427,908, 5,498,530, 5,770,434, 5,734,018, 5,698,426, 5,763,192, and 5,723,323.
- Furthermore, there are known techniques for obtaining human antibodies by panning with a human antibody library. For example, using a phage display method, the variable regions of human antibodies can be expressed as single chain antibodies (scFvs) on the surface of phages to select phages that bind to an antigen. The DNA sequences encoding the variable regions of human antibodies that bind to the antigen can be determined by analyzing the genes of selected phages. When the DNA sequences of scFvs that bind to the antigen are identified, human antibodies can be prepared by constructing appropriate expression vectors carrying these sequences and expressing the antibodies in adequate hosts introduced with the expression vectors. Such methods are already known (see WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, and WO 95/15388).
- As an alternative method, the phage display technique (McCafferty et al., Nature 348: 552-553 (1990)) can be used to produce human antibodies and antibody fragments in vitro from the immunoglobulin variable (V) domain gene repertoire of a non-immunized donor. Using this technique, an antibody V domain gene is cloned in frame with a coat protein gene of filamentous bacteriophage, for example, M13 or fd, and then displayed as a functional antibody fragment on the surface of phage particles. Since filamentous particles contain a single-stranded DNA copy of the phage genome, screening based on the functional properties of antibody results in selection of genes encoding an antibody having the properties. Thus, such phages mimic some characteristics of B cells. Phage display can be carried out in various modes; see, for example, Johnson, Kevin S, and Chiswell, David J., Current Opinion in Structural Biology 3: 564-571 (1993). There are some sources of V gene segments available for phage display. Clackson et al. (Nature, 352: 624-628 (1991)) have isolated numerous various anti-oxazolone antibodies from a small random combinatorial library of V genes derived from spleens of immunized mice. The V gene repertoire of a non-immunized human donor can be constructed, and antibodies against numerous various antigens (including self antigens) can be isolated by using the technique described in either of the following documents without modification: Marks et al., J. Mol. Biol. 222: 581-597 (1991) or Griffith et al., EMBO J. 12: 725-734 (1993). See also U.S. Pat. Nos. 5,565,332 and 5,573,905.
- The antibodies of the present invention also include functional antibody fragments such as Fab, Fab′, F(ab′)2, Fv, scFv, dsFv, Diabodies, and sc(Fv)2. Multimers (for example, dimers, trimers, tetramers, and polymers) of such a functional antibody fragment are also included in the antibodies of the present invention.
- Fab is a fragment with a molecular weight of about 50,000 that consists of L-chain and H-chain variable regions, and an H chain
fragment containing C H1 domain and a portion of hinge region. Fab is obtained by digesting IgG with papain in the presence of cysteine. In the present invention, an antibody described above can be digested with papain to prepare such Fab. Alternatively, a DNA encoding a portion of H chain and the L chain of an antibody described above is inserted into an appropriate vector. Fab can be prepared from transformants obtained by transformation using the vector. - Fab′ is a fragment with a molecular weight of about 50,000 obtained by cleaving the disulfide bond between the H chains of F(ab′)2 described below. In the present invention, such F(ab′)2 can be obtained by treating an above-described antibody by pepsin digestion, followed by cleavage of disulfide bond with a reducing agent. Alternatively, like Fab, Fab′ can be prepared by genetic engineering using DNA encoding Fab′.
- F(ab′)2 is a fragment with a molecular weight of about 100,000 obtained by digesting IgG with pepsin. F(ab′)2 is constituted by two (Fab′) fragments linked together via disulfide bond, each of which consists of L-chain and H-chain variable regions, and an H chain
fragment containing C H1 domain and a portion of hinge region. In the present invention, F(ab′)2 can be prepared by digesting an above-described antibody with pepsin. Alternatively, like Fab, F(ab′)2 can be prepared by genetic engineering using F(ab′)2-encoding DNAs. - Fv can be prepared by digesting an antibody into antibody fragments with an enzyme, for example, papain or pepsin. Alternatively, genes encoding antibody fragments are constructed and inserted into an expression vector. Fv can be expressed in appropriate host cells using the vector (see, for example, Co, M. S. et al., J. Immunol. 152, 2968-2976 (1994); Better, M. and Horwitz, A. H. Methods in Enzymology 178, 476-496 (1989); Plueckthun, A. and Skerra, A. Methods in Enzymology 178, 476-496 (1989); Lamoyi, E., Methods in Enzymology 121, 652-663 (1989); Rousseaux, J. et al., Methods in Enzymology 121, 663-669 (1989); Bird, R. E. et al., TIBTECH 9, 132-137 (1991)).
- scFv is a single-chain antibody fragment in which the C terminus of one Fv chain consisting of H-chain and L-chain variable regions is linked via an appropriate peptide linker to the N terminus of the other Fv chain. Such peptide linkers include, for example, flexible (GGGGS)3. For example, a DNA encoding an scFv antibody is constructed using DNAs encoding the H-chain variable region and L-chain variable region of an above-described antibody and a DNA encoding a peptide linker, and then inserted into an appropriate vector. Transformants are obtained by transformation with the resulting vector. scFv can be prepared from the transformants.
- dsFv is an Fv fragment whose H-chain and L-chain variable regions are stabilized with a disulfide bond formed by introducing Cys residues at appropriate positions in the H-chain and L-chain variable regions. In each chain, the position at which Cys residue is to be introduced is determined based on the conformation predicted by molecular modeling. In the present invention, for example, the conformation is predicted from the amino acid sequences of H-chain and L-chain variable regions of an above-described antibody. DNAs are constructed to encode H-chain and L-chain variable regions that have been introduced with mutations based on the prediction, and inserted into an appropriate vector. Transformants are obtained by transformation with the resulting vector. dsFv can be prepared from the transformants.
- Furthermore, multimers of antibody fragments can be prepared by linking scFv antibodies, dsFv antibodies, and the like via appropriate linkers, or fusing them to streptavidin. Fusion antibodies or labeled antibodies can be prepared from the antibodies (including antibody fragments) of the present invention by fusing or linking the antibodies with low molecular weight compounds, proteins, labeling substance, or the like. Such labeling substances include radioactive substances such as 125I.
- Diabody refers to a bivalent antibody fragment constructed by gene fusion (Holliger P et al., Proc. Natl. Acad. Sci. USA, 90: 6444-6448 (1993); EP 404,097; WO 93/11161). Diabodies are dimers consisting of two polypeptide chains, where each polypeptide chain has a VL and a VH linked via a linker short enough to prevent interaction of these two domains, for example, a linker of about five residues. The VL and VH linked together in a single polypeptide chain will form a dimer because the linker between them is too short to form a single-chain variable region fragment. As a result, the polypeptide chains form a dimer, and thus the diabody has two antigen binding sites. Diabodies can be prepared by treating an antibody with an enzyme, for example, papain or pepsin, to generate antibody fragments, or by constructing DNAs encoding those antibody fragments and introducing them into expression vectors, followed by expression in an appropriate host cell (see, for example, Co, M. S. et al., J. Immunol. 152, 2968-2976 (1994); Better, M. and Horwitz, A. H., Methods Enzymol. 178, 476-496 (1989); Pluckthun, A. and Skerra, A., Methods Enzymol. 178, 497-515 (1989); Lamoyi, E., Methods Enzymol. 121, 652-663 (1986); Rousseaux, J. et al., Methods Enzymol. 121, 663-669 (1986); Bird, R. E. and Walker, B. W., Trends Biotechnol. 9, 132-137 (1991)).
- sc(Fv)2 is a single-chain minibody produced by linking two VHs and two VLs using linkers and such (Hudson et al., J. Immunol. Methods 231: 177-189 (1999)). sc(Fv)2 can be produced, for example, by linking scFvs via a linker.
- The antibodies of the present invention also include fusion proteins in which an above-described antibody is fused with other peptides or proteins. The fusion protein can be prepared by linking a polynucleotide encoding an antibody of the present invention with a polynucleotide encoding a different peptide or polypeptide in frame, and introducing this into an expression vector and expressing it in a host. It is possible to use techniques known to those skilled in the art. Such a peptide or polypeptide to be fused with an antibody of the present invention include known peptides, for example, such as FLAG (Hopp, T. P. et al.,
BioTechnology 6, 1204-1210 (1988)), 6×His consisting of six His (histidine) residues, 10×His, influenza hemagglutinin (HA), human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40 T antigen fragment, lck tag, α-tubulin fragment, B-tag, and Protein C fragment. Furthermore, polypeptides to be fused with an antibody of the present invention include, for example, GST (glutathione-S-transferase), HA (influenza hemagglutinin), β-galactosidase, and MBP (maltose-binding protein). - The antibodies of the present invention also include antibodies linked to a labeling substance.
- Such labeling substances include, but are not limited to, enzymatic luminescence (luciferase), luminescent low-molecular-weight substances, fluorescent proteins, fluorescent low-molecular-weight substances, and radionuclides. Such radionuclides include, but are not limited to, γ-ray emitting nuclides such as 51Cr, 59Fe, 57Co, 67Ga, 75Se, 81mKr, 99mTc, 111In, 125I, 131I, 133Xe, and 201Tl, and positron-emitting nuclides such as 11C, 13N, 15O, 18F, 35mCl, 76Br, 45Ti, 48V, 60Cu, 61Cu, 62Cu, 66Ga, 89Zr, 94mTc, and 124I. “m” represents nuclear isomer, which is apparent to those skilled in the art.
- Fluorescent labels and luminescent labels include those using enzymatic luminescence (luciferase) and those using fluorescence (fluorescent proteins such as GFP, DsRed, and Kusabira Orange; and fluorescent low-molecular-weight substances such as FITC, Cy5.5, and Alexa Fluor 750).
- When enzymatic luminescence (luciferase) is used, it is necessary to administer a substrate separately.
- In particular, labels that have reduced influence from the animal's intrinsic fluorescence, and labels that emit a signal with high skin permeability are more preferred.
- The present invention also provides DNAs encoding an antibody of the present invention, vectors inserted with the DNAs, and transformed cells introduced with the vectors. The vectors include, for example, M13 vectors, pUC vectors, pBR322, pBluescript, and pCR-Script. Alternatively, when the objective is to subclone and excise cDNAs, the vectors include pGEM-T, pDIRECT, and pT7, in addition to those described. DNAs encoding an antibody of the present invention, vectors inserted with the DNAs, and transformed cells introduced with the vectors are prepared by known methods.
- DNAs encoding an antibody of the present invention that binds to the oxidized LDL/β2GPI complex include the following DNAs:
- (a) a DNA encoding a heavy chain having the nucleotide sequence of SEQ ID NO: 5;
- (b) a DNA encoding a light chain having the nucleotide sequence of SEQ ID NO: 10;
- (c) a DNA encoding a heavy chain that comprises CDR1 having the amino acid sequence of SEQ ID NO: 2, CDR2 having the amino acid sequence of SEQ ID NO: 3, and CDR3 having the amino acid sequence of SEQ ID NO: 4; and
- (d) a DNA encoding a light chain that comprises CDR1 having the amino acid sequence of SEQ ID NO: 7, CDR2 having the amino acid sequence of SEQ ID NO: 8, and CDR3 having the amino acid sequence of SEQ ID NO: 9.
- When an expression vector is used for expression in E. coli, for example, it should have the above-described characteristics which allow its amplification in E. coli. Additionally, when the host is E. coli such as JM109, DH5α, HB101, or XL1-Blue, the vector must have a promoter that allows efficient expression in E. coli, for example, lacZ promoter (Ward et al. Nature 341: 544-546 (1989); FASEB J. 6: 2422-2427 (1992)), araB promoter (Better et al. Science 240:1041-1043 (1988)), or T7 promoter. The vector also includes pGEX-5X-1 (Pharmacia), “QIAexpress system” (QIAGEN), pEGFP, and pET (for this vector, BL21, a strain expressing T7 RNA polymerase, is preferably used as the host), in addition to the above-described vectors.
- Furthermore, the vector may comprise a signal sequence for polypeptide secretion. When producing proteins into the periplasm of E. coli, the pelB signal sequence (Lei, S. P. et al. J. Bacteriol. 169: 4379 (1987)) may be used as a signal sequence for protein secretion. The vector can be introduced into host cell, for example, by the calcium chloride method or electroporation.
- In addition to E. coli expression vectors, the vector includes, for example, expression vectors derived from mammals (for example, pcDNA3 (Invitrogen), pEGF-BOS (Nucleic Acids Res. 18(17): 5322 (1990)), pEF, and pCDM8), insect cells (for example, “Bac-to-BAC baculovirus expression system” (GIBCO-BRL), pBacPAK8), plants (for example, pMH1 and pMH2), animal viruses (for example, pHSV, pMV, and pAdexLcw), retroviruses (for example, pZIPneo), yeasts (for example, “Pichia Expression Kit” (Invitrogen), pNV11, and SP-Q01), and Bacillus subtilis (for example, pPL608 and pKTHSO).
- In order to express proteins in animal cells, such as CHO, COS, and NIH3T3 cells, the vector must have a promoter necessary for expression in such cells, for example, SV40 promoter (Mulligan et al. Nature 277:108 (1979)), MMTV-LTR promoter, EF1α promoter (Mizushima et al. Nucleic Acids Res. 18: 5322 (1990)), CMV promoter, etc). It is even more preferable that the vector carries a gene for selecting transformants (for example, a drug-resistance gene that enables discrimination by a drug (such as neomycin and G418)). Vectors having such characteristics include, for example, pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.
- In addition, the following method can be used for stable gene expression and gene amplification in cells: CHO cells deficient in a nucleic acid synthesis pathway are introduced with a vector (for example, pCHOI) that carries a DHFR gene which compensates for the deficiency, and the gene is amplified using methotrexate (MTX). Alternatively, the following method can be used for transient gene expression: COS cells whose chromosome contains a gene for expression of SV40 T antigen are transformed with a vector (such pcD) having an SV40 origin of replication. It is also possible to use replication origins derived from polyoma virus, adenovirus, bovine papilloma virus (BPV), or such. To increase gene copy number in host cells, the expression vectors may further contain selection markers such as aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, E. coli xanthine-guanine phosphoribosyltransferase (Ecogpt) gene, and dihydrofolate reductase (dhfr) gene.
- Host cells to be introduced with the vectors are not particularly limited, and include, for example, E. coli and various types of animal cells. The host cells can be used, for example, as production systems for expressing and producing the antibodies of the present invention. The polypeptide production systems include in vitro and in vivo production systems. The in vitro production systems include production systems using eukaryotic or prokaryotic cells.
- When eukaryotic cells are used, for example, animal cells, plant cells, and fungal cells can be used as the host. Such animal cells include mammalian cells (for example, CHO (J. Exp. Med. 108, 945 (1995)), COS, 3T3, myeloma, baby hamster kidney (BHK), HeLa, and Vero), amphibian cells (for example, Xenopus oocyte (Valle, et al., Nature 291, 338-340 (1981))), and insect cells (for example, Sf9, Sf21, and Tn5). In the present invention, CHO-DG44, CHO-DXB11, COST cells, and BHK cells are preferably used. CHO cells are particularly preferred for large-scale expression in animal cells. The vectors can be introduced into host cells, for example, by calcium phosphate methods, DEAE-dextran methods, methods using cationic liposome DOTAP (Boehringer-Mannheim), electroporation, and lipofection.
- The plant cells include, for example, Nicotiana tabacum-derived cells, which are known as a protein production system and can be cultured as a callus. The fungal cells include yeasts, for example, the genus Saccharomyces such as Saccharomyces cerevisiae and Saccharomyces pombe; and filamentous bacteria, for example, the genus Aspergillus such as Aspergillus niger.
- When prokaryotic cells are used, production systems using bacterial cells are available. Such bacterial cells include E. coli, for example, JM109, DH5a, and HB101, and Bacillus subtilis. The antibodies of the present invention can be prepared in vitro by culturing cells transformed with a DNA of the present invention and purifying the antibodies by conventional methods that are routinely used by those skilled in the art.
- The present invention also provides host organisms that harbor a vector carrying a nucleic acid encoding an antibody of the present invention. The host organisms of the present invention are useful in producing recombinant antibodies. The host organisms of the present invention include goats. For example, transgenic goats of the present invention can be created by the method described below. Specifically, a fusion gene is constructed by inserting an antibody gene in frame within a gene encoding a protein (goat casein or such) intrinsically produced in milk. DNA fragments comprising the fusion gene which contains the inserted antibody gene are injected into goat embryos, and the resulting embryos are introduced into female goats. The antibodies of the present invention can be prepared from milk produced by transgenic animals born by the goats that received the embryos, or produced from progenies of these animals. Hormones can be given to the transgenic goats to increase the amount of milk containing the antibodies of the present invention produced by the goats (Ebert, K. M. et al., Bio/Technology 12, 699-702 (1994)).
- The present invention provides imaging agents for visualizing arteriosclerotic sites, which contain an antibody that binds to the oxidized LDL/β2GPI complex. The present invention also provides imaging methods for visualizing arteriosclerotic sites, which comprise a step of administering an antibody of the present invention that binds to the oxidized LDL/β2GPI complex to mammals. The imaging agents of the present invention are administered to mammals to visualize arteriosclerotic sites. Such mammals include humans and nonhuman mammals (for example, mice, rats, hamsters, rabbits, pigs, and monkeys). The imaging agents of the present invention are useful in diagnosing arteriosclerosis. The imaging agents of the present invention can be used both in vivo and in vitro.
- Arteriosclerotic symptoms are roughly divided into atheroma and calcified lesion. Atheroma sites in arteriosclerosis are especially stained by the imaging agents of the present invention.
- Atheroma is a pathological condition of arteriosclerosis. Macrophages are known to specifically take up via receptor oxidized LDL which contains a large amount of cholesterol, and thereby become foamy. The foamy macrophages accumulate and form plaques (atheromas) on the intima of a blood vessel.
- The imaging agent of the present invention is prepared by linking an imaging label or probe to an antibody that binds to the oxidized LDL/β2GPI complex, in particular, preferably antibody 3H3. The imaging label or probe enables direct or indirect monitoring.
- After in vivo administration (for example, intravenous administration) of an above-described probe, the distribution or amount accumulated can be assessed using an imagining device such as PET, SPECT, or CCD camera.
- Furthermore, in recent years, computer-aided tomography (computed tomography; “CT” also refers to computed tomography) has been applied in a clinical setting such as for disease diagnosis. Computer-aided tomography is a technology for generating an image of the interior of an object by scanning the object using a source of penetrating radiation, and processing the data in a computer.
- The CT technology is a technique for obtaining two-dimensional cross sectional patterns of objects (cross sections, etc.) by recording sectional images with positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), or the like. These examination techniques are often used not only for obtaining sectional images, but also for presenting three dimensional graphic images by integrating the two-dimensional images using the advanced computer-assisted image processing technology. Thus, the examination techniques are powerful tools for specifying the three-dimensional location of lesions, diagnosis, decision of operative strategy, and so on.
- For example, simple CT is used to obtain images by irradiating X ray or the like without using any contrast agent. Tissue edema, morphological abnormalities of bone, morphologies, and the like can be observed without using any contrast agent. Meanwhile, enhanced CT refers to CT in which images are taken after a contrast agent or the like having high X-ray absorption is injected into a blood vessel. Enhanced CT can be used to observe morphologies of blood vessels and tissues rich in blood flow. Furthermore, the so-called next-generation CT has been developed, and it can be used alone or in combination to detect the imaging agents of the present invention. Such next-generation CT is not particularly limited, and includes, for example, helical CT in which the irradiation source moves in a spiral manner, and multi-detector computed tomography (MDCT) (also referred to as multi-slice CT (MSCT)) in which detectors are arranged in multiple rows in the direction of body axis.
- When the labeled imaging probe (an imaging agent of the present invention) is a radionuclide with high X-ray absorption, CT can be used alone as a detector.
- Such labeling substances include, but are not limited to, enzymatic luminescence (luciferase), luminescent low-molecular-weight substances, fluorescent proteins, fluorescent low-molecular-weight substances, and radionuclides. Such radionuclides include, but are not limited to, γ-ray emitting nuclides such as 51Cr, 59Fe, 57Co, 67Ga, 75Se, 81mKr, 99mTc, 111In, 125I, 131I, 133Xe, and 201Tl, and positron-emitting nuclides such as 11C, 13N, 15O, 18F, 35mCl, 76Br, 45Ti, 48V, 60Cu, 61Cu, 62Cu, 66Ga, 89Zr, 94mTc, and 124I, “m” represents nuclear isomer, which is apparent to those skilled in the art. In particular, indium-111, technetium-99m, and iodine-131 can be particularly preferably used in two-dimensional scanning or single photon emission computed tomography (SPECT). Positron-emitting nuclide labels, for example, fluoride-19 can be particularly preferably used in positron emission tomography. Paramagnetic ions, for example, gadolinium (III) and manganese (II) can be particularly preferably used in magnetic resonance imaging (MRI).
- Such labeling substances include fluorescent labels, those using enzymatic luminescence (luciferase), and those using fluorescence (fluorescent proteins such as GFP, DsRed, and Kusabira Orange; and fluorescent low-molecular-weight substances such as, FITC, Cy5.5, and Alexa Fluor 750).
- When enzymatic luminescence (luciferase) is used, it is necessary to administer a substrate separately.
- In particular, labels that have reduced influence from the animal's intrinsic fluorescence are preferred, and labels that emit a signal with high skin permeability are more preferred.
- Magnetic resonance imaging (MRI), PET, and SPECT are used as an imaging detector. In particular, when fluorescent probes are used, CCD camera is preferably used as the monitoring device in terms of low invasiveness.
- For this reason, labels that emit light at a wavelength detectable by CCD camera, for example, about 350 to 900 nm, are preferred. Furthermore, devices that can be used to determine the intensity of light source inside the body based on values obtained by monitoring the body surface of a test animal with a CCD camera are preferred. When fluorescent labels are used, the image may be a reflection fluorescence image or transmission fluorescence image; however, it is preferable to capture both images. Furthermore, the fluorescence images can be observed three-dimensionally by superimposing multi-directionally recorded fluorescence images (regardless of reflection or transmission) and integrating information of the radiation source into the superimposed images. This processing is preferred because it enables reproduction of accurate three-dimensional locations and distribution. The three-dimensional images obtained by this method can also be further superimposed with CT images.
- When the labeled imaging probe is linked to a radionuclide with high X-ray absorption, CT can be used alone as the imaging detector (for example, PET or SPECT) as described above, and can also be used to determine the site, accumulated amount, and distribution of arteriosclerotic plaques.
- Alternatively, following in vivo administration (for example, intravenous administration) of the-above described labeled imaging probe, the labeled probe may be observed by CT alone or in combination with CCD. When CT is used in combination with CCD, for example, a CCD image of fluorescently labeled probe is superimposed with an image of simple CT (and/or an image of enhanced CT). Specifically, CT images resulting from simple-CT image extraction of organs such as bones and lungs (and/or enhanced-CT image extraction of blood vessels and tissues) are integrated with fluorescent probe images of major arterial lesions such as in the heart. This enables more accurate understanding of the site, accumulated amount, and distribution of arteriosclerotic plaques, three-dimensional positional relationships relative to tissues and blood vessels, and accurate three-dimensional images (localization) of arteriosclerotic plaques.
- The imaging agents of the present invention can be formulated, in addition to the antibodies, with pharmaceutically acceptable carriers by known methods. For example, the agents can be used parenterally, when the antibodies are formulated in a sterile solution or suspension for injection using water or any other pharmaceutically acceptable liquid. For example, the agents can be formulated by appropriately combining the antibodies of the present invention with pharmaceutically acceptable carriers or media, specifically, sterile water or physiological saline, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives, binding agents, and such, by mixing them at a unit dose and form required by generally accepted pharmaceutical practices. The content of active ingredient in such a formulation is adjusted so as to contain an appropriate dose within the specified range.
- Sterile compositions for injection can be formulated using vehicles such as distilled water for injection, according to standard formulation protocols.
- Aqueous solutions to be used for injection include, for example, physiological saline and isotonic solutions containing glucose or other adjuvants such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride. They may be used in combination with suitable solubilizers such as alcohol, specifically ethanol, polyalcohols such as propylene glycol and polyethylene glycol, and non-ionic surfactants such as
Polysorbate 80™ and HCO-50. - Oils include sesame oils and soybean oils, and can be combined with solubilizers such as benzyl benzoate or benzyl alcohol. They may also be formulated with buffers, for example, phosphate buffer or sodium acetate buffer; analgesics, for example, procaine hydrochloride; stabilizers, for example, benzyl alcohol or phenol; or antioxidants. The prepared injections are typically aliquoted into appropriate ampules.
- The administration is preferably parenteral, and specifically includes injection, intranasal administration, intrapulmonary administration, and percutaneous administration. For example, injections can be administered systemically or locally by intravenous injection, intramuscular injection, intraperitoneal injection, or subcutaneous injection.
- Furthermore, the method of administration can be appropriately selected depending on the patient's age and symptoms. The dosage of the imaging agents of the present invention can be selected, for example, from the range of 0.0001 to 1,000 mg per kg of body weight for each administration. Alternatively, the dosage may be, for example, in the range of 0.001 to 100,000 mg/person. However, the dosage is not limited to these values.
- The dose and method of administration vary depending on the subject's body weight, age, symptoms, and intensity of fluorescent labeling per mg antibody/sensitivity of detection device, and can be appropriately selected by those skilled in the art.
- The present invention also provides imaging kits for visualizing arteriosclerotic sites, which comprise an antibody of the present invention which binds to the oxidized LDL/β2GPI complex. The kits of the present invention visualize arteriosclerotic sites when administered to subjects. The above-described kits contain in addition to an antibody of the present invention, for example, injectors (apparatuses for drip infusion), adjuvants for suppressing non-specific adsorption (for example, albumin), and such, without limitation thereto.
- The kits may also contain items generally contained in kits, such as instruction manuals, appropriate containers, and control reagents used in imaging.
- The present invention provides methods of screening for candidate compounds as therapeutic agent for treating arteriosclerosis, which comprise the steps of:
- (a) administering to a nonhuman animal model of arteriosclerosis a candidate compound and an antibody of the present invention which binds to an oxidized LDL/O2GPI complex, for example, administering a candidate compound to a nonhuman animal model of arteriosclerosis that has been administered with an antibody of the present invention which binds to the oxidized LDL/β2GPI complex,
- (b) visualizing arteriosclerotic plaques in a nonhuman animal model of arteriosclerosis administered with the antibody and candidate compound, and in a nonhuman animal model of arteriosclerosis administered with the antibody but not with the candidate compound;
- (c) comparing arteriosclerotic plaques (for example, the size or site of arteriosclerotic plaques) between a nonhuman animal model of arteriosclerosis administered with the antibody and candidate compound and a nonhuman animal model of arteriosclerosis administered with the antibody but not with the candidate compound; and
- (d) selecting a candidate compound that reduces or eliminates arteriosclerotic plaques in a nonhuman animal model of arteriosclerosis administered with the antibody and candidate compound as compared to a nonhuman animal model of arteriosclerosis administered with the antibody but not with the candidate compound.
- Each step is performed using known techniques or techniques described above.
- Candidate compounds that can be used in the screening methods of the present invention include, but are not limited to, purified proteins (including antibodies), expression products of gene libraries, synthetic peptide libraries, DNA and RNA libraries (including functional nucleic acids such as aptamers and siRNAs), cell extracts, cell culture supernatants, and synthetic low-molecular-weight compound libraries.
- Nonhuman animal models of disease that can be used in the screening methods of the present invention include, but are not limited to, mice, hamsters, rats, rabbits, pigs, and monkeys.
- Arteriosclerosis model mice include, for example, transgenic mice in which a gene is overexpressed, and knockout mice that are deficient in a gene as a result of gene targeting. Arteriosclerosis models include, for example, apoE-deficient (apoE−/−) model (apoE (apolipoprotein E) is a protein that forms LDL which is known as bad cholesterol), LDL receptor-deficient (LDLR−/−) model, model introduced with human apoB, and model introduced with dominant apoE mutation. Such model mice also include
type 2 diabetes model mice (KKAy), and arteriosclerosis model mice which are produced by feeding C57BL6 mice with a high cholesterol diet or such. The C57BL6 line is known to have the greatest tendency of developing arteriosclerosis among mice, and mice of this line sometimes show arteriosclerotic plaques by simply feeding on a high cholesterol diet. - Arteriosclerotic plaques are sometimes seen in rabbits fed a high cholesterol diet for about 2.5 months. Furthermore, LDL receptor-deficient arteriosclerosis model rabbits include WHHL rabbits.
- A pig arteriosclerosis model is also known, which has a tendency to develop arteriosclerosis due to abnormality in the amino acid sequence of the LDL receptor-binding domain of apoB. Those skilled in the art can prepare arteriosclerosis model animals by referring to documents such as “Kessensho/Doumyakukoka Model Doubutu Sakuseihou (Methods for producing thrombosis/arteriosclerosis model animals), Ed., Koji Suzuki (Kinpodo)”. The resulting model animals can be used in the present invention.
- Compounds that reduce or eliminate arteriosclerotic plaques, which are selected by the screening methods of the present invention, are candidate compounds of therapeutic agents for arteriosclerosis. Thus, the present invention provides therapeutic agents for arteriosclerosis, which comprise as an active ingredient a substance selected by the screening methods of the present invention. The present invention also relates to the use of compounds selected by the screening methods of the present invention in manufacturing therapeutic agents for arteriosclerosis. When substances isolated by the screening methods of the present invention are used as a therapeutic agent, they can be used after they are formulated using known pharmaceutical production methods. For example, such substances are administered to patients in combination with pharmaceutically acceptable carriers or media (physiological saline, vegetable oils, emulsifiers, detergents, stabilizers, etc.). The substance is administered transdermally, nasally, transbronchially, intramuscularly, intravenously, or orally according to its properties. The dosage depends on the patient's age, weight, and symptoms, and the method of administration. However, those skilled in the art can select an appropriate dose.
- The nucleotide and amino acid sequences of the antibodies described herein are shown in the Sequence Listing according to the SEQ IDs shown below.
- SEQ ID NO: 1, the amino acid sequence of heavy-chain variable region
- SEQ ID NO: 2, the amino acid sequence of heavy chain CDR1
- SEQ ID NO: 3, the amino acid sequence of heavy chain CDR2
- SEQ ID NO: 4, the amino acid sequence of heavy chain CDR3
- SEQ ID NO: 5, the nucleotide sequence of heavy-chain variable region
- SEQ ID NO: 6, the amino acid sequence of light-chain variable region
- SEQ ID NO: 7, the amino acid sequence of light chain CDR1
- SEQ ID NO: 8, the amino acid sequence of light chain CDR2
- SEQ ID NO: 9, the amino acid sequence of light chain CDR3
- SEQ ID NO: 10, the nucleotide sequence of light-chain variable region
- All prior art documents cited in the specification are incorporated herein by reference.
- Hereinbelow, the present invention will be specifically described with reference to the Examples, but is not to be construed as being limited to the illustrative embodiments described in the Examples.
- 600 μg of human LDL (Organon Teknika Corp., Durham, N.C.) was oxidized in 2 ml of PBS containing 5 μM CuSO4 at 37° C. for 12 hours. The oxidization was terminated by adding 1 mM EDTA.
- 0.2 mg/ml oxidized LDL described above was incubated at a final concentration of 0.2 mg/ml with human β2GPI (purchased from Affinity Biologicals) at 37° C. for 16 hours to form the oxidized LDL/β2GPI complex.
- Purified protein of human oxidized LDL/β2GPI complex was mixed with the same amount of complete adjuvant (SIGMA; F5881). BALB/c mice (female) were immunized through footpads with the resulting emulsion at 5 to 50 μg/head every three to seven days several times. Three to five days after the final immunization, inguinal lymph nodes were excised from the mice, and fused with cells of mouse myeloma P3U1 (P3-X63Ag8U1).
- Cell fusion was carried out based on the conventional method described below. For every medium, fetal bovine serum (FBS) was used after inactivation by incubation at 56° C. for 30 minutes. P3U1 was prepared by culturing in RPMI1640-10% FBS (containing penicillin and streptomycin).
- Cells from excised mouse inguinal lymph nodes were combined with P3U1 at a ratio of 10:1 to 2:1. The mixed cells were centrifuged. As a fusion enhancing agent, 50% polyethylene glycol 4000 (Merck; gas chromatography grade PEG4000, Catalog No. 9727) was added little by little to the precipitated cells while gently mixing to achieve cell fusion. Then, RPMI1640 was added little by little to the mixture with gentle mixing. The resulting mixture was centrifuged. The precipitated fused cells were appropriately diluted with HAT medium containing 15% FCS(RPMI1640, HAT-supplement (Invitrogen; 11067-030), penicillin, and streptomycin), and plated at 200 μl/well in 96-well microplates.
- The fused cells were cultured in a CO2 incubator (5% CO2, 37° C.). When the cells were sufficiently grown as colonies, screening was carried out by sampling the culture supernatants.
- In the screening, positive clones were selected by ELISA (described in Example 4) using 96-well plates coated with the human oxidized LDL/β2GPI complex, which was the same as that used as the immunizing antigen. The clones were expanded using HT medium (RPMI1640, HT-supplement (Invitrogen; 21060-017), penicillin, and streptomycin) containing 15% FCS, and then cloned into single clones by the limiting dilution method. This screening which used the anti-human oxidized LDL/β2GPI complex antibody as an immunogen yielded seven types of hybridoma clones including clone 3H3.
- The ELISA for detecting an anti-human oxidized LDL/β2GPI complex antibody was carried out by the method described below. Specifically, 50 μl of 1 μg/ml oxidized LDL/β2GPI was added to each well of microplates (Nunc; Maxisorp). The plates were incubated at 4° C. overnight to adsorb the complex, and then blocked with 1% BSA. Antibody samples were diluted using an assay buffer (1% BSA, 0.15 M NaCl/20 mM HEPES (pH 7.4)) to the antibody concentrations indicated on the horizontal axis. 50 μl of each sample was added to the wells, and the wells were incubated for 30 minutes. The solutions were discarded, and the wells were washed with 0.1
% Tween 20/PBS. Then, 50 μl of 2,000-times diluted HRP-labeled anti-mouse IgG (MBL code 330) was added to each well of the plates, and incubated for 30 minutes. The solutions were discarded, and the wells were washed with 0.1% Tween 20/PBS. Then, 50 μl of substrate TMB (MOSS; TMBZ) was added, and the plates were incubated at room temperature for three minutes. After the reaction was terminated by adding 50 μl of 0.18 M sulfuric acid, detection was carried out using absorbance at 450 nm (FIG. 1A ). - To detect the reactivity to β2GPI, ELISA was carried out by the method described below. Specifically, 50 μl of 1 μg/ml β2GPI was added to each well of microplates (Nunc; Maxisorp). The plates were incubated at 4° C. overnight to adsorb β2GPI, and then blocked with 1% BSA. Antibody samples were diluted using the assay buffer (1% BSA, 0.15 M NaCl/20 mM HEPES (pH 7.4)) to the antibody concentrations indicated on the horizontal axis. 50 μl of each sample was added to the wells, and incubated for 30 minutes. The solutions were discarded, and the wells were washed with 0.1
% Tween 20/PBS. Then, 50 μl of 2,000-times diluted HRP-labeled anti-mouse IgG (MBL code 330) was added to each well of the plates, and incubated for 30 minutes. The solutions were discarded, and the wells were washed with 0.1% Tween 20/PBS. Then, 50 μl of substrate TMB (MOSS; TMBZ) was added, and the plates were incubated at room temperature for three minutes. After the reaction was terminated by adding 50 μA of 0.18 M sulfuric acid, detection was carried out using absorbance at 450 nm (FIG. 1B ). - Furthermore, various concentrations of β2GPI (up to 50 μg/ml) were prepared and added at 50 μl/well to microplates (Nunc; Maxisorp). The plates were incubated at 4° C. overnight to adsorb β2GPI. Then, the antibody reactivity was tested in the same manner (data not shown).
- The result showed that the reactivity towards the immobilized oxidized LDL/β2GPI complex was: 2H6>3H3, 2A12, 3D4>4C12, 1H4. Alternatively, the reactivity towards the immobilized β2GPI was: 2H6, 3D4>2A12, 4F10. 3H3 and 4C12 were not reactive to the immobilized β2GPI (
FIGS. 1A and B). - However, when the coating concentration in microtiter plates was increased, 3H3 also exhibited reactivity (data not shown).
- Next, as a method for assessing antibody reactivity, inhibition test using a free antigen was carried out to evaluate the specificity of each antibody.
- In the reactivity assay (ELISA) for immobilized human oxidized LDL/β2GPI complex and β2GPI, an inhibitory reaction to immobilized antigen was carried out by having oxidized LDL/β2GPI complex or β2GPI together when the antibodies were added in the reaction (Schematic diagram of assay system is shown in
FIG. 2 ). - Specifically, 50 μl of 1 μg/ml β2GPI was added to each well of microplates (Nunc; Maxisorp). The plates were incubated at 4° C. overnight to adsorb β2GPI, and then blocked with 1% BSA. Antibody samples were diluted to appropriate concentrations using the assay buffer (1% BSA, 0.15 M NaCl/20 mM HEPES (pH 7.4)), and samples of oxidized LDL/β2GPI complex or β2GPI, which serves as a competitive antigen, were diluted to the antigen concentrations indicated on the horizontal axis. 25 μl each of the diluted antibody sample and antigen sample were added to the wells, and the wells were incubated for 30 minutes. The solutions were discarded, and the wells were washed with 0.1
% Tween 20/PBS. Then, 50 μl of 2,000-times diluted HRP-labeled anti-mouse IgG (MBL code 330) was added to each well of the plates, and the plates were incubated for 30 minutes. The solutions were discarded, and the wells were washed with 0.1% Tween 20/PBS. Then, 50 μl of substrate TMB (MOSS; TMBZ) was added, and the plates were incubated at room temperature for three minutes. After the reaction was terminated by adding 50 μl of 0.18 M sulfuric acid, detection was carried out using absorbance at 450 nm. - The result showed that when the coexisting oxidized LDL/β2GPI complex was the free antigen in ELISA, the binding of 3H3, 4C12, and 2A12 to immobilized oxidized LDL/β2GPI was markedly inhibited, while β2GPI did not inhibit the binding. On the other hand, the binding of 2H6 was inhibited when the free antigen was the oxidized LDL/β2GPI complex, and the mixing with β2GPI also inhibited the binding to some extent. As for 3D4, stronger inhibition was observed with β2GPI than with oxidized LDL/β2GPI complex as free antigen (
FIG. 3 ). - From the results above, reactivity of antibodies can be summarized as shown in Table 1 (Table 1 is shown in Example 7). 3H3 showed similar reactivity to 4C12, but was not the same reactivity, and had different specificity.
- ApoE−/− mice and LDLR−/− mice (obtained from Jackson Lab, and maintained in the animal experiment facility at Okayama University) were fed a common diet (Oriental Yeast NMF) up to eight weeks old, and then fed a high fat diet (common diet additionally containing 1% cholesterol, 1% cholic acid, and 15% salt-free butter) for four to six months. As a result, arteriosclerotic plaques developed, and thus thickening and atheroma were observed in the thoracic or abdominal aorta. Then, these eight-month-old mice were sacrificed. Cryosections of the thoracic aorta, and aortic root and valves were prepared from the mice, and observed as samples.
- The prepared cryosections were fixed with paraformaldehyde and then used in the experiment of fluorescent antibody immunostaining.
- Labeling of Monoclonal Antibody with Cy5.5
- Various monoclonal antibodies (1 mg/ml) were dialyzed against 0.1 M carbonate buffer (pH 9.3) at 4° C. overnight, and each was transferred into Fluorolink Cy5.5 monofunctional dye (1 tube). After 30 minutes of incubation at room temperature, the antibodies were treated with a SephadexG-25 column to yield Cy5.5-labeled antibody.
- Sections were fixed with 1% paraformaldehyde for five minutes, and then incubated with various monoclonal antibodies at 4° C. overnight. After washing, the sections were incubated with an FITC-labeled anti-mouse IgG or IgM antibody (secondary antibody) at room temperature for one hour. Staining with DAPI and Rhodamine Phalloidin was carried out by addition with the secondary antibody at the time of incubation. Then, the sections were observed and photographed under a fluorescent microscope.
- The result showed that when used in fluorescent immunostaining of C57BL6 mice fed a normal diet, both antibodies 3H3 and Mac3 stained atheroma resulting from accumulation of foamy macrophages. 3H3 stained the same areas (
FIG. 4 ). - Fluorescent immunostaining of the aortic valve in arteriosclerosis-prone model mice (apoE−/− fed a high fat diet) was compared to the result obtained using different antibodies that recognize the oxidized LDL/β2GPI complex. Antibodies positive for atheroma in the staining were only antibodies 3H3 and A (
FIG. 5 ). - Thus, the present invention enables arteriosclerotic plaque-specific immunostaining using various atheroma-specific monoclonal antibodies labeled with Cy5.5, Alexa, or the like.
- Imaging was performed using IVIS™ Imaging System, IVIS 200, from Xenogen (excitation, 640 nm; emission, 720 nm).
- Experiment 1: Cy5.5-labeled monoclonal antibody (0.25 mg/ml) was administered at 0.15 ml/head via the caudal vein to apoE−/− mice fed a high fat diet, which were prepared by the same method as described in Example 6. The following three were administered: physiological saline (PBS; control), Cy5.5-labeled antibody A, and Cy5.5-labeled antibody 3113. Twenty four hours after administration, the mice were photographed alive for the full-body image after removing their thoracic skin (
FIG. 7 ). - Experiment 2: Then, the heart intact with thoracic aorta was excised and photographed (
FIG. 7 ). The aortic root was intensely stained by 3113 administration. Antibody A also stained to some extent; however, the fluorescence intensity was weaker as compared to 3H3. There was no stain with 2A12. - The fluorescence intensity was determined per unit area of the aortic root. The fluorescence of PBS-administered control mouse was taken as 1.0. When 3H3 was administered, fluorescence was three times stronger than the control. There was no significant change in the fluorescence intensity when other antibodies were administered (
FIG. 10 ). - The specificity assessment of the antibodies described above is summarized in Table 1.
-
TABLE 1 ANTIBODIES SPECIFIC TO OXDIZED LDL/β2GPI COMPLEX COMPETITIVE BINDING TO INHIBITION IMMOBILIZED (IMMOBILIZED ANTIGEN OXIDIZED LDL/β2GPI) OXIDIZED OXIDIZED OXIDIZED IMMUNO- β2GPI LDL/β2GPI β2GPI LDL/β2GPI STAINING 1H4 − + ND ND − 2A12 + ++ − ++ − 2H6 ++ +++ ++ ++ − 3D4 ++ ++ ++ − − 3H3 − ++ − ++ +++ 4C12 − + − ++ − 4F10 + − ND ND − - β2GPI was added as an inhibitory, competitive antigen to the immobilized oxidized LDL/β2GPI complex or immobilized β2GPI, and the resulting inhibition was assessed by ELISA. The result is as follows: in the case of immobilized oxidized LDL/β2GPI complex, 3D4>2H6>4C12>3H3; and in the case of immobilized β2GPI, 2H6>3D4 (4C12 and 3H3 bound only weakly to immobilized β2GPI). 3H3 was highly specific to the free (non-denatured) form of oxidized LDL/β2GPI complex in a solution.
- Four monoclonal antibody clones analyzed were: 3H3, 4C12, 2H6, and 3D4.
- The antibody subclasses of the four clones are as follows: 3H3 and 4C12 are IgG2b; and 2H6 and 3D4 are IgG1.
- Hybridomas which produce four types of monoclonal antibodies (3H3, 4C12, 2H6, and 3D4) were each cultured in RPMI1640 supplemented with 10% FCS. mRNAs were obtained from the hybridomas using the QuickPrep micro mRNA purification kit (Amersham Biosciences; code 27-9255-01). The mRNAs were converted into cDNAs using the First-Strand cDNA Synthesis kit (Amersham Biosciences; code 27-9261-01). Gene amplification was achieved by PCR using the cDNAs as a template. PCR was carried out using the 11 types of primer combinations listed below. The sequences of primers MKV1 to MKV11 were designed by analyzing the signal sequences of numerous various monoclonal antibodies. Thus, the 11 types of primer sequences can cover the L chain signal of almost every monoclonal antibody. An L-chain variable region of interest is amplified by using at least a single PCR pattern selected from 11 PCR patterns using combinations of the 11 types of MKV primers with primer MKC which corresponds to the sequence of a mouse L-chain constant region.
- The PCR conditions are shown below.
-
cDNA derived from mouse hybridoma 4 μl 2.5 mM dNTPs 4 μl one of the 11 types of primers MKV1 to MKV11 (20 μM) 2.5 μl MKC primer (20 μM) 2.5 μl DMSO 2.5 μl ×10 pfu polymerase buffer 5 μl pfu polymerase 1 μl sterile water 28.5 μl Total 50 μl - 94° C. for 1 min, 55° C. for 2 min, 72° C. for 2 min (30 cycles)
- 4° C., no time restriction
- The DNA sequences of primers are shown below.
-
(SEQ ID NO: 11) MKV1 primer: ATGAAGTTGCCTGTTAGGCTGTTGGTGCTG (SEQ ID NO: 12) MKV2 primer: ATGGAGWCAGACACACTCCTGYTATGGGTG (SEQ ID NO: 13) MKV3 primer: ATGAGTGTGCTCACTCAGGTCCTGGSGTTG (SEQ ID NO: 14) MKV4 primer: ATGAGGRCCCCTGCTCAGWTTYTTGGMWTCTTG (SEQ ID NO: 15) MKV5 primer: ATGGATTTWCAGGTGCAGATTWTCAGCTTC (SEQ ID NO: 16) MKV6 primer: ATGAGGTKCYYTGYTSAGYTYCTGRGG (SEQ ID NO: 17) MKV7 primer: ATGGGCWTCAAGATGGAGTCACAKWYYCWGG (SEQ ID NO: 18) MKV8 primer: ATGTGGGGAYCTKTTTYCMMTTTTTCAATTG (SEQ ID NO: 19) MKV9 primer: ATGGTRTCCWCASCTCAGTTCCTTG (SEQ ID NO: 20) MKV10 primer: ATGTATATATGTTTGTTGTCTATTTCT (SEQ ID NO: 21) MKV11 primer: ATGGAAGCCCCAGCTCAGCTTCTCTTCC (SEQ ID NO: 22) MKC primer: ACTGGATGGTGGGAAGATGG (M = A or C; R = A or G; W = A or T; S = C or G; Y = C or T; K = G or T) - Combinations of PCR primers responsible for the amplification of each L-chain variable region by PCR are as follows:
- The L-chain variable region genes amplified by PCR were inserted into pCR2.1 vector (Invitrogen).
- The DNA nucleotide sequence of PCR2.1 vector inserted with an L-chain variable region gene was determined using a DNA sequencer (Applied Biosystems; 3130 Genetic Analyzer).
- Hybridomas which produce four types of monoclonal antibodies (3H3, 4C12, 2H6, and 3D4) were each cultured in RPMI1640 supplemented with 10% FCS. mRNAs were obtained from the hybridomas using the QuickPrep micro mRNA purification kit (Amersham Biosciences; code 27-9255-01). The mRNAs were converted into cDNAs using the First-Strand cDNA Synthesis kit (Amersham Biosciences; code 27-9261-01). Amplification of H chain variable region genes was achieved by PCR using the cDNAs as a template. PCR was carried out using the 12 types of primer combination listed below. The sequences of primers MHV1 to MHV12 were designed by analyzing the signal sequences of numerous various monoclonal antibodies. Thus, the 12 types of primer sequences can cover the H chain signal of almost every monoclonal antibody. An H-chain variable region of interest is amplified by using at least a single PCR pattern selected from 12 PCR patterns using combinations of the 12 types of MHV primers with primer MHCG2b or MHCG1 which corresponds to the sequence of a mouse H-chain constant region. Primer MHCG2b corresponds to the sequence of an H-chain constant region of mouse IgG2b, while primer MHCG1 corresponds to the sequence of an H-chain constant region of mouse IgG1. Thus, primer MHCG2b was used in the PCR amplification of clones 3H3 and 4C12, which are of the IgG2b subclass. Primer MHCG1 was used in the PCR amplification of clones 2H6 and 3D4, which are of the IgG1 subclass.
- The PCR conditions are shown below.
-
cDNA derived from mouse hybridoma 4 μl 2.5 mM dNTPs 4 μl one of the 12 types of primers MHV1 to MHV12 (20 μM) 2.5 μl MHCG2b or MHCG1 primer (20 μM) 2.5 μl DMSO 2.5 μl ×10 pfu polymerase buffer 5 μl pfu polymerase 1 μl sterile water 28.5 μl Total 50 μl - 94° C. for 1 min, 55° C. for 2 min, and 72° C. for 2 min (30 cycles)
- 4° C., no time restriction
- The DNA sequences of primers are shown below.
-
(SEQ ID NO: 23) MHV1 primer: ATGAAATGCAGCTGGGGCATSTTCTTC (SEQ ID NO: 24) MHV2 primer: ATGGGATGGAGCTRTATCATSYTCTT (SEQ ID NO: 25) MHV3 primer: ATGAAGWTGTGGTTAAACTGGGTTTTT (SEQ ID NO: 26) MHV4 primer: ATGRACTTTGGGYTCAGCTTGRTTT (SEQ ID NO: 27) MHV5 primer: ATGGACTCCAGGCTCAATTTAGTTTTCCTT (SEQ ID NO: 28) MHV6 primer: ATGGCTGTCYTRGSGCTRCTCTTCTGC (SEQ ID NO: 29) MHV7 primer: ATGGRATGGAGCKGGRTCTTTMTCTT (SEQ ID NO: 30) MHV8 primer: ATGAGAGTGCTGATTCTTTTGTG (SEQ ID NO: 31) MHV9 primer: ATGGMTTGGGTGTGGAMCTTGCTATTCCTG (SEQ ID NO: 32) MHV10 primer: ATGGGCAGACTTACATTCTCATTCCTG (SEQ ID NO: 33) MHV11 primer: ATGGATTTTGGGCTGATTTTTTTTATTG (SEQ ID NO: 34) MHV12 primer: ATGATGGTGTTAAGTCTTCTGTACCTG (SEQ ID NO: 35) MHCG2b primer: CAGTGGATAGACTGATGGGGG (SEQ ID NO: 36) MHCG1 primer: CAGTGGATAGACAGATGGGGG (M = A or C; R = A or G; W = A or T; S = C or G; Y = C or T; K = G or T) - Combinations of PCR Primers Responsible for the Amplification of Each H-Chain variable region by PCR are as follows:
- The H-chain variable region genes amplified by PCR were inserted into the pCR2.1 vector (Invitrogen).
- The DNA nucleotide sequence of the PCR2.1 vector inserted with an H-chain variable region gene was determined using a DNA sequencer (Applied Biosystems; 3130 Genetic Analyzer).
- Thus, the amino acid sequence of 3H3 and its CDRs were revealed, and can be used in the present invention (
FIG. 11 ). - The amino acid and nucleotide sequences of the antibodies of the present invention are shown in the Sequence Listing according to the following SEQ IDs shown below.
- SEQ ID NO: 1, the amino acid sequence of heavy-chain variable region
- SEQ ID NO: 2, the amino acid sequence of heavy chain CDR1
- SEQ ID NO: 3, the amino acid sequence of heavy chain CDR2
- SEQ ID NO: 4, the amino acid sequence of heavy chain CDR3
- SEQ ID NO: 5, the nucleotide sequence of heavy-chain variable region
- SEQ ID NO: 6, the amino acid sequence of light-chain variable region
- SEQ ID NO: 7, the amino acid sequence of light chain CDR1
- SEQ ID NO: 8, the amino acid sequence of light chain CDR2
- SEQ ID NO: 9, the amino acid sequence of light chain CDR3
- SEQ ID NO: 10, the nucleotide sequence of light-chain variable region
- Experiments were carried out to generate three-dimensional (localization) images of arteriosclerotic plaques by integrating computed tomography (CT) images.
- Fluorescence imaging was carried out using IVIS 200 Imaging System (Xenogen) (for Cy5.5, [excitation, 640 nm; emission, 720 nm]; for Alexa Fluor 750, [excitation, 745 nm; emission, 800 nm]). 0.25 mg/ml Cy5.5-labeled antibody 3H3 (IgG) or 1.0 to 1.5 mg/ml Alexa Fluor 750-labeled antibody 3H3 was administered at 0.15 ml/head via the caudal vein to ApoE−/− mice fed a high fat diet, and after two to 24 hours under inhalation anesthesia, in vivo fluorescence was observed and photographed using IVIS 200. The ApoE−/− mice were observed after shaving, because their black hair absorbs fluorescence. First, the fluorescence was observed with reflected light, and then with transmitted light. Three-dimensional (3D) images of mice were generated and integrated with the light source information (
FIG. 9A : a three-dimensional image by IVIS before integration). In the figure, red dots correspond to fluorescent signals from labels linked to 3H3. The denser red dots mean stronger fluorescence intensity, showing the localization of the imaging agent. - After 3D CT analysis, the mice were euthanized, and the hearts were perfused with 10 ml of PBS. The hearts and aortae were excised and their reflection fluorescence images were obtained using IVIS 200.
- CT imaging was performed using eXplore Locus CT System (GE Healthcare). Under inhalation anesthesia, the same mice used in the IVIS 200 imaging were irradiated with X ray to obtain CT images.
- Using general-purpose 3D visualization software (Amira; Mercury Computer Systems), fluorescent images detected by IVIS 200 were integrated with images obtained using CT (
FIG. 9B : a three-dimensional CT image after integration). - The procedure is shown schematically (
FIG. 8 ). - (A) IVIS 200 fluorescence imaging using a specific antibody (reflection).
- (B) IVIS 200 fluorescence image obtained using a specific antibody (transmitted light; left) and CT image (middle) before integration, and integrated image (right). In the fluorescence image (transmitted light; left), as the red dots become denser, the fluorescence intensity becomes stronger, suggesting that the imaging agent is localized and accumulated at the position (site that exhibits stronger binding reactivity to 3H3).
- (C) Image resulting from integration of IVIS fluorescent signal and three-dimensional CT image: the photograph shows a three-dimensional image generated as animation in a computer-generated virtual space (three-dimensional graphic animation). The sites labeled were observed from multiple angles.
- The visible light is absorbed by the body while the light of near-infrared wavelengths is hardly absorbed by the body. Thus, near-infrared fluorescent labels are suitable for in vivo imaging. In this experiment, antibodies labeled with Cy5.5 or Alexa Fluor 750 were administered to mice via the caudal vein, and the resulting fluorescence was monitored with IVIS 200 to assess the measurement conditions for the reflection and transmission fluorescence. When ApoE−/− mice with arteriosclerosis were observed by in vivo reflection fluorescence imaging using a Cy5.5-labeled antibody, intense signals were found in the aortic valve and thoracic aorta. Furthermore, by ex vivo imaging and ex vivo fluorescence microscopy, the fluorescently labeled antibody administered into the vein was demonstrated to be localized in arteriosclerotic plaques. However, when a Cy5.5-labeled antibody was used, the signal of transmission fluorescence was weak and thus it was difficult to identify the site of fluorescence in the three-dimensional (3D) images. By contrast, when an Alexa Fluor 750-labeled antibody was used, specific intense signals were observed two hours after intravenous administration in both reflection and transmission fluorescence images. In the generated three-dimensional image, intense fluorescent signals were recognized in the chest (
FIGS. 8A and B, left panels). Then, the same mice were photographed by CT. The image (FIG. 8B , middle panel) resulting from extraction of bones and lungs from CT image was integrated with an IVIS 200 fluorescent image by Amira. The resulting integrated 3D image (FIG. 8B , right panel) showed that the presence of fluorescent signals in and around the heart. In the figure, the denser red dots suggest stronger fluorescence intensity, showing the localization of the imaging agent. CT image (middle panel) and 3D-CT integrated image (FIG. 8B , right panel) are shown. A three-dimensional image was generated as animation in a computer-generated virtual space (three-dimensional graphic animation). The sites labeled were observed from multiple angles (FIG. 8C ). - The experimental result described above showed that when ApoE−/− mice with arteriosclerosis were observed by in vivo reflection fluorescence imaging using fluorescently labeled antibody 3H3, intense signals were found in the aortic valve and thoracic aorta. Furthermore, by ex vivo imaging and ex vivo fluorescence microscopy, the fluorescently labeled antibody administered into the vein was demonstrated to be localized in arteriosclerotic plaques.
- The experiment described above demonstrated not only that arteriosclerosis in mice could be visualized by using a near-infrared fluorescent substance (Cy5.5 or Alexa 750)-labeled antibody, but also that the images could be integrated with three-dimensional CT images. Furthermore, it has been demonstrated that such antibodies enable detection of human arteriosclerotic plaques. The experimental results described herein will lead to clinically applicable technologies for diagnostic imaging. In addition, the mouse imaging techniques are already practicable as a screening system for drug discovery.
- The sites (locations) of arteriosclerosis cannot be identified by conventional tests for arteriosclerosis. In contrast, the present invention provides non-invasive diagnostic methods that allow visual identification of the site and size of arteriosclerotic plaques (in particular, atheroma and atherosclerosis).
- A screening system for therapeutic agents to treat atherosclerosis can be constructed by using arteriosclerosis-prone model mice (for example, apoE-deficient (ApoE−/−) mice; which maintain high plasma cholesterol level, and spontaneously develop an atherosclerosis-like condition) and antibodies for the imaging.
- Furthermore, an imaging system for clinical diagnosis can be constructed by converting the antibodies into humanized antibodies. Thus, plaques or such detached from atheroma lesions of arteries are known to cause arterial embolism which leads to cerebral embolism or myocardial infarction. Methods for monitoring human arthrosclerosis which progresses insidiously, asymptomatically, and chronically can be expected to benefit strategies for preventing or treating lifestyle-related diseases.
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-162565 | 2008-06-20 | ||
JP2008162565 | 2008-06-20 | ||
PCT/JP2009/054473 WO2009154025A1 (en) | 2008-06-20 | 2009-03-09 | ANTIBODY AGAINST OXIDIZED LDL/β2GPI COMPLEX AND USE OF THE SAME |
Publications (2)
Publication Number | Publication Date |
---|---|
US20110182816A1 true US20110182816A1 (en) | 2011-07-28 |
US8575314B2 US8575314B2 (en) | 2013-11-05 |
Family
ID=41433943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/000,319 Active 2029-05-15 US8575314B2 (en) | 2008-06-20 | 2009-03-09 | Antibody against oxidized LDL/β2GPI complex and use of the same |
Country Status (7)
Country | Link |
---|---|
US (1) | US8575314B2 (en) |
EP (1) | EP2319869B1 (en) |
JP (1) | JP5616592B2 (en) |
KR (1) | KR20110038047A (en) |
CN (1) | CN102124030B (en) |
CA (1) | CA2728473A1 (en) |
WO (1) | WO2009154025A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110182817A1 (en) * | 2008-06-20 | 2011-07-28 | Eiji Matsuura | Antibody against calcified globule and use of the same |
US10434141B2 (en) | 2016-05-31 | 2019-10-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
CN114716547A (en) * | 2022-05-18 | 2022-07-08 | 珠海丽禾医疗诊断产品有限公司 | Binding protein comprising antigen binding domain and production method and application thereof |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201302779A (en) * | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | Fusion proteins & combination vaccines |
WO2013157105A1 (en) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | Mucin 5ac specific human antibody and use thereof |
WO2013157102A1 (en) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | Mucin 5ac specific human antibody and use thereof |
CA2975295A1 (en) | 2015-02-02 | 2016-08-11 | Novadaq Technologies Inc. | Methods and systems for characterizing tissue of a subject |
US10026159B2 (en) * | 2015-09-23 | 2018-07-17 | Novadaq Technologies ULC | Methods and system for management of data derived from medical imaging |
US11096602B2 (en) | 2016-07-29 | 2021-08-24 | Stryker European Operations Limited | Methods and systems for characterizing tissue of a subject utilizing a machine learning |
CN112500490B (en) * | 2020-10-14 | 2022-05-03 | 华南农业大学 | F (ab) of anti-levofloxacin antibody2Fragment, preparation method and application thereof |
Citations (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5432018A (en) * | 1990-06-20 | 1995-07-11 | Affymax Technologies N.V. | Peptide library and screening systems |
US5498530A (en) * | 1991-10-16 | 1996-03-12 | Affymax Technologies, N.V. | Peptide library and screening method |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5571689A (en) * | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5585089A (en) * | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5627024A (en) * | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5723323A (en) * | 1985-03-30 | 1998-03-03 | Kauffman; Stuart Alan | Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof |
US5734018A (en) * | 1988-05-02 | 1998-03-31 | The Regents Of The University Of California | Peptide mixtures |
US5763192A (en) * | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5766905A (en) * | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
US5770434A (en) * | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US5900359A (en) * | 1993-09-29 | 1999-05-04 | Yamasa Corporation | Method for determination of oxidized lipoproteins and use thereof |
US6375925B1 (en) * | 1996-11-08 | 2002-04-23 | The Regents Of The University Of California | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
US6716410B1 (en) * | 1999-10-26 | 2004-04-06 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
US20040241858A1 (en) * | 2001-09-07 | 2004-12-02 | Eiji Matsuura | Ligand specific to b2-glycoprotein I and use thereof |
US20060099644A1 (en) * | 2002-09-06 | 2006-05-11 | Eiji Matsuura | Method of assaying oxidized ldl-beta 2-glycoprotein i complexin vivo |
US20060194270A1 (en) * | 2003-02-21 | 2006-08-31 | Eiji Matsuura | Method for measuring oxidized ldl-crp complex and measurement kit |
US20080160018A1 (en) * | 1988-12-28 | 2008-07-03 | Pdl Biopharma, Inc. | Humanized immunoglobulins |
US20100081149A1 (en) * | 2006-05-30 | 2010-04-01 | Okayama Prefecture Industrial Promotion Foundation | Novel oxidized ldl complex and method for detection thereof |
US20110182817A1 (en) * | 2008-06-20 | 2011-07-28 | Eiji Matsuura | Antibody against calcified globule and use of the same |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58201994A (en) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | Method for producing antigen-specific human immunoglobulin |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
ES2139598T3 (en) | 1990-07-10 | 2000-02-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF SPECIFIC UNION COUPLE MEMBERS. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
DE69229477T2 (en) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methods for the production of humanized antibodies |
ATE207080T1 (en) | 1991-11-25 | 2001-11-15 | Enzon Inc | MULTIVALENT ANTIGEN-BINDING PROTEINS |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DE69333823T2 (en) | 1992-03-24 | 2006-05-04 | Cambridge Antibody Technology Ltd., Melbourn | METHOD FOR PRODUCING MEMBERS OF SPECIFIC BINDING SAVINGS |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
JP4044972B2 (en) | 1994-02-24 | 2008-02-06 | 協和メデックス株式会社 | Monoclonal antibody recognizing human atherosclerotic lesion-associated antigen |
AU7104294A (en) | 1994-06-10 | 1996-01-05 | Symbiotech, Inc. | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH11511977A (en) | 1995-09-07 | 1999-10-19 | ノボ ノルディスク アクティーゼルスカブ | Phage display for detergent enzyme activity |
AU715608B2 (en) | 1996-03-20 | 2000-02-03 | Morphosys Ag | Purification of tissue plasminogen activator (tPA) |
WO1997046251A1 (en) | 1996-06-06 | 1997-12-11 | Lajolla Pharmaceutical Company | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES |
AU735015B2 (en) | 1996-06-10 | 2001-06-28 | Scripps Research Institute, The | Use of substrate subtraction libraries to distinguish enzyme specificities |
EP0929361A4 (en) | 1996-10-04 | 2000-07-19 | Whatman Inc | Device and method for simultaneous multiple chemical syntheses |
DK0934526T3 (en) | 1996-10-08 | 2003-05-05 | Bisys B V U | Methods and means for selecting peptides and proteins that have specific affinity for a target |
CA2270869A1 (en) | 1996-11-06 | 1998-05-14 | Genentech, Inc. | Constrained helical peptides and methods of making same |
IL119587A (en) | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
IL119586A (en) | 1996-11-07 | 2001-09-13 | Univ Ramot | Discontinuous library of a single biological unit and a method for its preparation |
JP4184437B2 (en) | 1996-11-27 | 2008-11-19 | ボストン ハート ファウンデイション インコーポレイテッド | Novel low density lipoprotein binding proteins and their use in the diagnosis and treatment of atherosclerosis |
-
2009
- 2009-03-09 EP EP09766473.4A patent/EP2319869B1/en active Active
- 2009-03-09 CN CN200980132253.1A patent/CN102124030B/en active Active
- 2009-03-09 WO PCT/JP2009/054473 patent/WO2009154025A1/en active Application Filing
- 2009-03-09 KR KR1020117001534A patent/KR20110038047A/en not_active Application Discontinuation
- 2009-03-09 US US13/000,319 patent/US8575314B2/en active Active
- 2009-03-09 CA CA2728473A patent/CA2728473A1/en not_active Abandoned
- 2009-06-19 JP JP2009146783A patent/JP5616592B2/en active Active
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5723323A (en) * | 1985-03-30 | 1998-03-03 | Kauffman; Stuart Alan | Method of identifying a stochastically-generated peptide, polypeptide, or protein having ligand binding property and compositions thereof |
US5763192A (en) * | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
US5734018A (en) * | 1988-05-02 | 1998-03-31 | The Regents Of The University Of California | Peptide mixtures |
US5571689A (en) * | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5403484A (en) * | 1988-09-02 | 1995-04-04 | Protein Engineering Corporation | Viruses expressing chimeric binding proteins |
US5663143A (en) * | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5585089A (en) * | 1988-12-28 | 1996-12-17 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20080160018A1 (en) * | 1988-12-28 | 2008-07-03 | Pdl Biopharma, Inc. | Humanized immunoglobulins |
US5693762A (en) * | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5693761A (en) * | 1988-12-28 | 1997-12-02 | Protein Design Labs, Inc. | Polynucleotides encoding improved humanized immunoglobulins |
US6180370B1 (en) * | 1988-12-28 | 2001-01-30 | Protein Design Labs, Inc. | Humanized immunoglobulins and methods of making the same |
US5498538A (en) * | 1990-02-15 | 1996-03-12 | The University Of North Carolina At Chapel Hill | Totally synthetic affinity reagents |
US5580717A (en) * | 1990-05-01 | 1996-12-03 | Affymax Technologies N.V. | Recombinant library screening methods |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5723286A (en) * | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
US5432018A (en) * | 1990-06-20 | 1995-07-11 | Affymax Technologies N.V. | Peptide library and screening systems |
US5698426A (en) * | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
US5770434A (en) * | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US5498530A (en) * | 1991-10-16 | 1996-03-12 | Affymax Technologies, N.V. | Peptide library and screening method |
US5900359A (en) * | 1993-09-29 | 1999-05-04 | Yamasa Corporation | Method for determination of oxidized lipoproteins and use thereof |
US5627024A (en) * | 1994-08-05 | 1997-05-06 | The Scripps Research Institute | Lambdoid bacteriophage vectors for expression and display of foreign proteins |
US5766905A (en) * | 1996-06-14 | 1998-06-16 | Associated Universities Inc. | Cytoplasmic bacteriophage display system |
US6375925B1 (en) * | 1996-11-08 | 2002-04-23 | The Regents Of The University Of California | Methods and reagents for non-invasive imaging of atherosclerotic plaque |
US6716410B1 (en) * | 1999-10-26 | 2004-04-06 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
US20040241858A1 (en) * | 2001-09-07 | 2004-12-02 | Eiji Matsuura | Ligand specific to b2-glycoprotein I and use thereof |
US7160733B2 (en) * | 2001-09-07 | 2007-01-09 | Eiji Matsuura | Ligand specific to β2-glycoprotein I and use thereof |
US20060099644A1 (en) * | 2002-09-06 | 2006-05-11 | Eiji Matsuura | Method of assaying oxidized ldl-beta 2-glycoprotein i complexin vivo |
US7455976B2 (en) * | 2002-09-06 | 2008-11-25 | Eiji Matsuura | Method of measuring oxidized LDL/β2-glycoprotein I complex occurring in the living body |
US20060194270A1 (en) * | 2003-02-21 | 2006-08-31 | Eiji Matsuura | Method for measuring oxidized ldl-crp complex and measurement kit |
US20100081149A1 (en) * | 2006-05-30 | 2010-04-01 | Okayama Prefecture Industrial Promotion Foundation | Novel oxidized ldl complex and method for detection thereof |
US20110182817A1 (en) * | 2008-06-20 | 2011-07-28 | Eiji Matsuura | Antibody against calcified globule and use of the same |
Non-Patent Citations (7)
Title |
---|
Casset et al (2003. Biochemical and Biophysical Research Communications. 307: 198-205) * |
Chen et al (1999. Journal of Molecular Biology. 293: 865-881) * |
Holm et al (2007. Molecular Immunology. 44: 1075-1084) * |
MacCallum et al (1996. Journal of Molecular Biology. 262: 732-745) * |
Pascalis et al (2002. Journal of Immunology. 169:3076-3084) * |
Vajdos et al (2002. Journal of Molecular biology. 320: 415-428), * |
Wu et al (1999. Journal of Molecular Biology. 294: 151-162) * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110182817A1 (en) * | 2008-06-20 | 2011-07-28 | Eiji Matsuura | Antibody against calcified globule and use of the same |
US8410251B2 (en) | 2008-06-20 | 2013-04-02 | National University Corporation Okayama University | Antibody against calcified globule and use of the same |
US10434141B2 (en) | 2016-05-31 | 2019-10-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
CN114716547A (en) * | 2022-05-18 | 2022-07-08 | 珠海丽禾医疗诊断产品有限公司 | Binding protein comprising antigen binding domain and production method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN102124030B (en) | 2015-06-17 |
WO2009154025A1 (en) | 2009-12-23 |
CN102124030A (en) | 2011-07-13 |
KR20110038047A (en) | 2011-04-13 |
JP2011042581A (en) | 2011-03-03 |
US8575314B2 (en) | 2013-11-05 |
EP2319869A1 (en) | 2011-05-11 |
JP5616592B2 (en) | 2014-10-29 |
EP2319869B1 (en) | 2016-08-17 |
CA2728473A1 (en) | 2009-12-23 |
EP2319869A4 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8575314B2 (en) | Antibody against oxidized LDL/β2GPI complex and use of the same | |
US8410251B2 (en) | Antibody against calcified globule and use of the same | |
WO2011074621A1 (en) | Mesothelin (msln) antibody and use thereof | |
US8858949B2 (en) | Antibodies that specifically bind to a beta oligomers and use thereof | |
EP2419447B1 (en) | Antibodies that specifically bind to a beta oligomers and use thereof | |
US9139655B2 (en) | Tumor-targeting monoclonal antibodies to FZD10 and uses thereof | |
CA2800565C (en) | Anti-icam-1 single domain antibody and uses thereof | |
CN103491983B (en) | The material relevant to cardiovascular imaging and method | |
US9771423B2 (en) | Anti-VCAM-1 nanobodies | |
Sasaki et al. | In vivo distribution of single chain variable fragment (scFv) against atherothrombotic oxidized LDL/β2-glycoprotein I complexes into atherosclerotic plaques of WHHL rabbits: implication for clinical PET imaging | |
JP2015502744A (en) | Antibodies for molecular imaging of vulnerable plaque in atherosclerosis | |
JP2008518629A (en) | Association of MDL-1 with tumor and method thereof | |
US9637542B2 (en) | CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease | |
Freise | ImmunoPET imaging of murine CD4+ T cells using an anti-mouse CD4 antibody fragment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., JAP Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOJIMA, KAZUO;REEL/FRAME:026110/0842 Effective date: 20110214 Owner name: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MATSUURA, EIJI;REEL/FRAME:026110/0820 Effective date: 20110217 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
CC | Certificate of correction | ||
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD.;REEL/FRAME:055750/0603 Effective date: 20210319 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |